Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines

The disclosure is drawn to a method of using novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description

This is a divisional of application Ser. No. 08/286,096 filed on Aug. 4, 1994 which is a continuation of Ser. No. 07/926,091 filed Aug. 13, 1992 now abandoned which is a continuation in part of Ser. No. 07/771,576, filed on Oct. 4, 1991 now abandoned for NOVEL 7-SUBSTITUTED-9-SUBSTITUTED AMINO-6-DEMETHYL-6-DEOXYTETRACYCLINES. This application is a reissue of 08/455,446, filed May 31, 1995, now Pat. No. 5,529,990, which is a divisional of application Ser. No. 08/286,096, filed on Aug. 4, 1994, now Pat. No. 5,494,903, which is a continuation of Ser. No. 07/926,091, filed Aug. 13, 1992, now abandoned, which is a continuation-in-part of Ser. No. 07/771,576, filed on Oct. 4, 1991, now abandoned for NOVEL 7-SUBSTITUTED-9-SUBSTITUTED AMINO-6-DEMETHYL-6-DEOXYTETRACYCLINES.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to novel [4S-(4,12aα)]-4-(dimethylamino)-7-(substituted)-9-(substituted amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamides hereinafter called 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines, which exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines and are useful as antibiotic agents. The invention also relates to novel 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracycline intermediates useful for making the novel compounds of the present invention and to novel methods for producing the novel compounds and intermediate compounds.

DESCRIPTION OF THE PRIOR ART

A variety of tetracycline antibiotics have been synthesized and described for the treatment of infectious diseases in man and animals since 1947. Tetracyclines inhibit protein synthesis by binding to the 30S subunit of the bacterial ribosome preventing binding of aminoacyl RNA (Chopra, Handbook of Experimental Pharmacology, Vol. 78, 317-392, Springer-Verlag, 1985). Resistance to tetracyclines has emerged among many clinically important microorganisms which limit the utility of these antibiotics. There are two major mechanisms of bacterial resistance to tetracyclines: a) energy-dependent efflux of the antibiotic mediated by proteins located in the cytoplasmic membrane which prevents intracellular accumulation of tetracycline (S. B. Levy, et al., Antimicrob. Agents Chemotherapy 33, 1373-1374 (1989); and b) ribosomal protection mediated by a cytoplasmic protein which interacts with the ribosome such that tetracycline no longer binds or inhibits protein synthesis (A. A. Salyers, B. S. Speers and N. B. Shoemaker, Mol. Microbiol, 4:151-156, 1990). The efflux mechanism of resistance is encoded by resistance determinants designated tetA-tetL. They are common in many Gram-negative bacteria (resistance genes Class A-E), such as Enterbacteriaceae, Pseudomonas, Haemophilus and Aeromonas, and in Gram-positive bacteria (resistance genes Class K and L), such as Staphylococcus, Bacillus and Streptococcus. The ribosomal protection mechanism of resistance is encoded by resistance determinants designated TetM, N and O and is common in Staphylococcus, Streptococcus, Campylobacter, Gardnerella, Haemophilus and Mycoplasma (A. A. Salyers, B. S. Speers and N. B. Shoemaker, Mol. Microbiol, 4:151-156 1990).

A particularly useful tetracycline compound is 7-(dimethylamino)-6-demethyl-6-deoxytetracycline, known as minocycline (see U.S. Pat. Nos. 3,148,212, Re. 26,253 and 3,226,436 discussed below). However, strains harboring the tetB (efflux in gram-negative bacteria) mechanism, but not tetK (efflux in Staphylococcus) are resistant to minocycline. Also, strains carrying tetM (ribosomal protection) are resistant to minocycline. This invention describes the synthesis of novel tetracycline compounds which demonstrate significant in vitro and in vivo activity vs. tetracycline and minocycline susceptible strains and some tetracycline and minocycline resistant strains, that is, those harboring the tetM (ribosomal protection) resistance determinants.

Duggar, U.S. Pat. No. 2,482,055, discloses the preparation of Aureomycin®(I) by fermentation which have antibacterial activity. Growich et al., U.S. Pat. No. 3,007,965, disclose improvements to the fermentation preparation of I. Neither of these patents teaches of suggests the 6-demethyl-6-deoxy-tetracyclines.
Beereboom et al., U.S. Pat. No. 3,043,875 discloses tetracycline derivatives of the formulae (II) and (III) where R is H or CH3; R1 is H and when R is CH3, OH; R2 is H and N(CH3)2; X and Y are halogen; Z is H and halogen and B is bromo, chloro and iodo, which have anti-bacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl) amino or mono(lower alkyl)amino substitutents (at Y or Z) and an amino function (at B).
Boothe et al., U.S. Pat. No. 3,148,212, reissued as Re. 26,253, and Petisi et al., U.S. Pat. No. 3,226,436, discloses tetracycline derivatives of the formula (IV) wherein R is hydrogen or methyl and R1 and R2 is hydrogen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R1 and R2 cannot both be hydrogen, which are useful for treating bacterial infections. This patent does not teach or suggest the inclusion of a 9-amino functionality (at R2).
Blackwood et al., U.S. Pat. No. 3,200,149 discloses tetracycline derivatives of the formulae (V) and (VI) and reduction products thereof wherein Y may be hydrogen or hydroxyl, X may be hydrogen, chloro, iodo, or bromo, X1 may be hydrogen, amino, and lower alkanoyl-amino, X2 may be hydrogen or nitro and Z is chloro or fluoro which possess microbiological activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino group (at X) and another nitrogen functionality (at X1) on the 6-demethyl-6-deoxy-tetracycline nucleus.
Petisi et al., U.S. Pat. No. 3,338,963 discloses tetracycline compounds of the formula (VII) wherein R1 and R2 are hydrogen, nitro, amino, formylamino, acetyl-amino, p-(di-hydroxyboryl)benzoylamino, p-(aminobenzene-sulfonyl)amino, chlorine, bromine or diazonium with the proviso that R1 and R2 may not both be hydrogen and with the further proviso that when R1 is chlorine or bromine, R2 may not be hydrogen and vice versa, R3 is hydrogen or methyl and R4 is hydrogen or hydroxy, which have broad-spectrum antibacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R1) and amino substituents (at R2).
Bitha et al., U.S. Pat. No. 3,341,585 discloses tetracycline compounds of the formula (VIII) wherein R5 is hydrogen, α-hydroxy or β-hydroxy, R6 is α-methyl or β-methyl, and R7 and R9 are each hydrogen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R7 and R9 cannot both be hydrogen and with the further proviso that when R5 is hydrogen then R6 is α-methyl. A preferred embodiment of the general formula (VIII) is when R5 is α-hydroxy or β-hydroxy, R6 is α-methyl or β-methyl, R7 is di(lower alkyl)amino and R9 is hydrogen, which have broad-spectrum antibacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R7) and amino substituents (at R9).
Shu, U.S. Pat. No. 3,360,557 discloses 9-hydroxy-tetracyclines of the formula (IX) wherein R1 is hydrogen or hydroxy, R2 is hydrogen or hydroxy, R3 is hydrogen or methyl, R2 and R3 taken together is methylene, and R4 is hydrogen, halogen, nitro, amino, mono(lower alkyl)amino or di(lower alkyl)amino, which have been found to possess antibacterial activity. This patent is restricted to 9-hydroxytetracyclines and does not teach or suggest the presently claimed compounds.
Zambrano, U.S. Pat. No. 3,360,561 discloses a process for preparing 9-nitrotetracyclines of the formula (X) wherein R5 is hydrogen or hydroxy, R1 is hydrogen or hydroxy, R6 is hydrogen or methyl, R1 and R6 taken together is methylene, R7 is hydrogen, chloro or nitro and R9 is hydrogen or nitro with the proviso that R7 and R9 cannot both be hydrogen. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent (at R7) and an amino functionality (at R9).
Martell et al., U.S. Pat. No. 3,518,306 discloses 7-and/or 9-(N-nitrosoalkylamino)-6-demethyl-6-deoxy-tetracyclines of the formula (XI) which possess in vivo antibacterial activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent at (C-7) and an amino functionality (at C-9).

In U.S. Pat. No. 5,021,407, a method of overcoming the resistance of tetracycline resistant bacteria is disclosed. The method involves utilizing a blocking agent compound in conjunction with a tetracycline type antibiotic. This patent does not disclose novel tetracycline compounds which themselves have activity against resistant organisms.

In summary, none of the above patents teach or suggest the novel compounds of this application. In addition, none of the above patents teach or suggest novel tetracycline compounds having activity against tetracycline and minocycline resistant strains as well as strains which are normally susceptible to tetracyclines.

SUMMARY OF THE INVENTION

This invention is concerned with novel 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines, represented by formula I and II, which have antibacterial activity; with method of treating infectious diseases in warm blooded animals employing these new compound; with methods of treating or controlling veterinary diseases; with pharmaceutical preparations containing these compounds; with novel intermediate compounds and processes for the production of these compounds. More particularly, this invention is concerned with compounds of formula I and II which have enhanced in vitro and in vivo antibiotic activity against tetracycline resistant strains as well as a high level of activity against strains which are normally susceptible to tetracyclines.

In formula I and II, X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;

and when X=NR1R2 and R1=hydrogen,

    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
      and when R1=methyl or ethyl,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
      and when R1=n-propyl,
    • R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
      and when R1=1-methylethyl,
    • R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
      and when R1=n-butyl,
    • R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
      and when R1=1-methylpropyl,
    • R2=2-methylpropyl;

R is selected from R4(CH2)nCO— or R4′(CH2)nSO2—;

and when R=R4(CH2)nCO— and n=0,

    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C1-C4)alkyl group selected from aminomethyl, α-amino-ethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto(C1-C3)alkyl group selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl,
    • or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl,
    • or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinylgroup [substituted selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substituted selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl or RaRb is (C2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropylamino; (C2-C5)azacycloalkyl group such as aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or 2-methylpyrrolidinyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and their optional isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)-aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl, 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl; or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRbamino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R—R(CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (C2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4 (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C1-C4)carboxyalkyl group; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; RaRbamino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio or n-propylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; mercapto group; mono- or di-straight or branched (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkycarbonyl, (C6-C10)-aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methyl indolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl, or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl, or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;

and when X=NR1R2 and R1=hydrogen,

    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R1=methyl or ethyl,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;

R is selected from R4(CH2)nCO— or R4′(CH2)nSO2—;

and when R=R4(CH2)nCO— and n=0,

    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino-(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methyltoluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl) such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substituted selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substituted selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (C2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaR3 is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRb amino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (C2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo,(C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 3-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tertbutoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from the amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, triahlo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy, iso-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C4)carboxyalkyl group;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl-2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl,benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholino; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, β-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Particularly preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;

and when X=NR1R2 and R1=hydrogen,

    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
      and when R1=methyl or ethyl,
    • R2—methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
    • R is selected from R4(CH2)nCO— or R4′(CH2)nSO2—;
      and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino—(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl,chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five-membered aromatic ring with two N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused therein:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)alkoxycarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methylbenzoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorometyyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10) aryl group (substitution selected from halo,(C1-C4)alkoxy, triahlo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-tolyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromophenylcarbonyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as from 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one, N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from the amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2) 2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl; 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4) alkoxy, trihalo (C1-C3) alkyl, nitro, amino, cyano, (C1-C4) alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl )
    • such as γ--butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together as —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Most particularly preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;

and when X=NR1R2 and R1=hydrogen,

    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
      and when R1=methyl or ethyl,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
    • R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); carboxy(C2-C6)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkylxoy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethoxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto;
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to two N, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C6)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methoxypropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tertbutoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′(CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, triahlo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto: ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl or ethyl; C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4) alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
    •  
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxo-thiomorpholino; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, or β-naphthyl; (C7-C10)aralkyl group such as benzyl,1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto;
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (C2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen:
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C5)alkoxy, oxygen, sulfur or unsubstituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Compounds of special interest are compounds according to the above formula I and II in which X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine chlorine, fluorine or iodine;

and when X=NR1R2 and R1=methyl or ethyl;

    • R2=methyl or ethyl, R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—;
      and when R=R4 (CH2)nCO— and n=0,
    • R4 is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, or S heteroatom optionally having a benzo or pyrido ring fused thereto:

 such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:

    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl )
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C2)alkyl group, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, (C1-C6)alkoxycarbonyl), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C2)alkyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl, ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, or 1-(1,2,3-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, amino, (C1-C4)alkoxycarbonyl); acryloxy or haloacyloxy group selected from acetyl, propionyl or chloroacetyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methoxypropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, (C1-C4)alkoxycarbonyl); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O or S heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Also included in the present invention are compounds useful as intermediate for producing the above compounds of formula I and II. Such intermediate compounds include those having the formula:
wherein formula III and IV, Y is NO2;

    • R is selected from R4(CH2)nCO— or R4, (CH2)nSO2—;
      and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto(C1-C3)alkyl group selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)alkoxycarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzyl, (C1-C4)alkylbenzoyl such as 4-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl,
    • or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, triahlo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorometyyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl];
    • (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substituted selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyll, O or S;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; amino; straight or branched (C1-C6)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; (C2-C5)azacycloalkyl group such as aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or 2-methylpyrrolidinyl; carboxy(C2-C4) alkylamino group selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)-aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl, 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl,benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such a γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4, (CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4) alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from—N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C1-C4)carboxyalkyl group; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio or n-propylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl, C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group, mercapto group; mono- or di- straight or branched (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4) alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such a imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3) alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, β-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxo-thiomorpholinyl; or —(CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Preferred compounds are compounds according to the above formula III and IV in which Y is NO2;

R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and when R=R4(CH2)nCO— and n=0,

    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methyltoluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, β-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nCO— and n=−4,
    • R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl,4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4) alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4) alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl; pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)-alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkyloxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl,
    • or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidazinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy, iso-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C4)carboxyalkyl group;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl,benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3-alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidazinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxo-thiomorpholinyl; or CCH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Particularly preferred compounds are compounds according to the above formula III and IV in which Y is NO2;

R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and when R=R4(CH2)nCO— and n=0,

    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino-(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclo-propyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methylbenzoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3) alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10) aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as-pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromophenylcarbonyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as from 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
  • and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
  • and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (C2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methyl indolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C2)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Most particularly preferred compounds are compounds according to the above formula III and IV in which Y is NO2;

    • R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—;
  • and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrollyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy,trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C3-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
  • and when R=R4 (CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
  • and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
  • and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom;
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, β-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

Compounds of special interest are compounds according to the above formula III and IV in which Y is NO2;

    • R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, or S heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O or S heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O or S heteroatoms and an adjacent appended O heteroatom:
    •  (A is selected from hydrogen; straight or branched (C1-C2)alkyl; C6-aryl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C2)alkyl group, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C2)alkyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl;
  • and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, or 1-(1,2,3-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, amino, (C1-C4)alkoxycarbonyl); acyloxy or haloacyloxy group selected from acetyl, propionyl or chloroacetyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
  • and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, (C1-C4)alkoxycarbonyl); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O or S heteroatom optionally having a benzo or pyrido ring fused thereto:
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O or S heteroatoms optionally having a benzo or pyrido ring fused thereto:
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl;
  • and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W (CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine;and the pharmacologically acceptable organic and inorganic salts or metal complexes.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The novel compounds of the present invention may be readily prepared in accordance with the following schemes.

The starting 7-(substituted amino)-6-de-methyl-6-deoxytetracyclines described in formula 1, wherein X=NR1NR2 and R1=R2 (1a) and X═NHR1 (1b) or the salts thereof are prepared by procedures known to those skilled in the art including those described in U.S. Pat. Nos. 3,226,436 and 3,518,306.

The starting 7-(substituted amino)-6-de-methyl-6-deoxytetracyclines described in formula 1 wherein X=NR1R2 and R1=R2 (1c) are prepared according to Scheme 1.

In accordance with Scheme 1, a 7-(monoalkylamino)-6-demethyl-6-deoxytetracycline, 1b in which X=NHR1, is reductively alkylated with an aldehyde to give an unsymmetrical dialkylamino, 1c.

In accordance with Scheme II, a 7-(substituted amino)-6-demethyl-6-deoxytetracycline or its salts, 1a or 1c, is treated with

    • a) a metal nitrate salt; such as calcium, potassium or sodium; and a strong acid; such as sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid or
    • b) nitric acid and a strong acid; such as sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid; to form the corresponding 7-(substituted amino)-9-nitro-6-demethyl-6-deoxytetracycline 2.

To produce the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, compound 2 or its salts is treated with hydrogen in an acidic alcohol solvent, in the presence of a suitable catalyst such as, for example:

    • a) any supported catalyst; such as 0.5-23% palladium-on-carbon, 0.5-25% palladium-on-barium, 0.5-25% platinum-on-carbon or 0.5-25% rhodium-on-carbon;
    • b) any reducible supported catalyst; such as Raney nickle or platinum oxide; or
    • c) a homogeneous hydrogenation catalyst; such as tris(triphenylphosphine)rhodium (I) chloride; to obtain the 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracycline, 3.

Alternatively, the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, are obtained by treating with:

    • a) stannous chloride dihydrate as described by R. B. Woodward, Org. Syn., Coll. Vol. 3, 453 (1955);
    • b) a soluble metal sulfide, preferably sodium sulfide, in alcoholic solvents as described by G. R. Robertson, Org. Syn., Coll. Vol. 1, 52 (1941);
    • c) an active metal in mineral acid; such as iron, tin or zinc in dilute hydrochloric acid;
    • d) active metal couples; such as copper-zinc, tin-mercury or aluminum amalgam in dilute acid; or
    • e) transfer hydrogenation using triethylammonium formate and a supported catalyst as described by I. D. Entwistle et al., J. Chem. Soc., Perkin 1, 443 (1977).

Preferably, the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate.

SCHEME III

In accordance with Scheme III, a 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracycline or its salts, 3, is treated with an acyl chloride, acyl anhydride, mixed acyl anhydride, sulfonyl chloride or sulfonyl anhydride in the presence of a suitable acid scavenger in a variety of solvents to form the corresponding 9-(acyl or sulfonyl amino)-7-(substituted amino)-6-demethyl-6-deoxytetracycline, 4. The acid scavenger is selected from sodium bicarbonate, sodium acetate, pyridine, triethylamine, N,O-bis(trimethylsilyl)acetamide, N,O-bis(trimethylsilyl)trifluoroacetamide or a basic ion-exchange resin. The solvents are selected from water-tetrahydrofuran, N-methylpyrrolidone, 1,3-dimethyl-2-imidazolidone, hexamethylphosphoramide, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone or 1,2-dimethoxyethane.

Alternatively, in accordance with Scheme III, a 9-(acylamino)-6-demethyl-6-deoxytetracycline, 5a, prepared by the procedures described in U.S. Pat. No. 3,239,499, or a 9-(sulfonylamino)-6-demethyl-6-deoxytetracycline, 5b, prepared by the procedures described in this invention, is treated with a halogenation agent such a bromine, N-bromoacetamide, N-bromosuccinimide, iodine monochloride, benzyltrimethylammonium chloride iodine monochloride complex or N-iodosuccinimide to give the corresponding 9-(acyl or sulfonylamino)-7-halo-6-demethyl-6-deoxytetracycline, 6.

Similarly, compound 5a or 5b can be treated with:

    • a) a metal nitrate such as calcium, potassium or sodium; and a strong acid such as sulfuric, trifluoroacetic, methanesulfonic acid or trifluoromethanesulfonic; or
    • b) nitric acid and a strong acid such as sulfuric, trifluoroacetic, methanesulfonic, trifluoromethanesulfonic or perchloric acid to give the corresponding 9-(acyl or sulfonyl amino)-7-nitro-6-demethyl-6-deoxytetracycline, 7.

In accordance with Scheme IV, 9-(acyl or sulfonyl amino)-7-nitro-6-demethyl-6-deoxytetracycline, 7, is selectively N-alkylated with aldehydes or ketones in the presence of acid and hydrogen to the corresponding 7,9-di(substituted amino)-6-demethyl-6-deoxytetracycline, 8, by methodology known to those skilled in the art (U.S. Pat. Nos. 3,226,436 and 3,518,306).

    • 4 X=NR1R2(R1=R2 or R1≠R2)
    • 6 X=halogen
    • 7 Y=NO2
    • 8 X=NHR3(R3=R1 or R2)

In accordance with Scheme V, Compounds 4,6,7 or 8 are selectively N-alkylated in the presence of formaldehyde and either a primary amine such as methylamine, ethylamine, benzylamine, methyl glycinate, (L or D)lysine, (L or D)alanine or their substituted congeners; or a secondary amine such morpholine, pyrrolidine, piperidine or their substituted congeners to give the corresponding Mannich base adduct, 9,10,11 or 12, or the desired intermediate or of the biologically active 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines. Contemplated equivalents include those substituted morpholine, pyrrolidine or piperidine moieties wherein the substituents are chosen to provide the requisite increase in solubility without adversely affecting antibacterial activity.

The 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines may be obtained as metal complexes such as aluminum, calcium, iron, magnesium, manganese and complex salts; inorganic and organic salts and corresponding Mannich base adducts using methods known to those skilled in the art (Richard C. Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, 1989). Preferably, the 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate; or organic salts such as acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate alkylsulfonate or arylsulfonate. In all cases, the salt formation occurs with the C(4)-dimethylamino group. The salts are preferred for oral and parenteral administration.

BIOLOGICAL ACTIVITY

Methods for in Vitro antibacterial evaluation (Tables I-V)

The minimum inhibitory concentration (MIC), the lowest concentration of the antibiotic which inhibits growth of the test organism, is determined by the agar dilution method using 0.1 ml Muller-Hinton II agar (Baltimore Biological Laboratories) per well. An inoculum level of 1-5×105 CFU/ml, and a range of antibiotic concentrations (32-0.004 μg/ml) is used. MIC is determined after the plates are incubated for 18 hours at 35° C. in a forced air incubator. The test organisms comprise genetically defined strains that are sensitive to tetracycline and resistant strains that are insensitive to tetracycline, either by preventing the antibiotic from interacting with bacterial ribosomes (tetM) or by a tetK encoded membrane protein which confers tetracycline resistance by energy-dependent efflux of the antibiotic from the cell.

E. coli in Vitro Protein translation System (Table VI)

An in vitro, cell free, protein translation system using extracts from E. coli strain MRE 600 (tetracycline-sensitive) and a derivative of MRE 600 containing the tetM determinant has been developed based on literature methods. [J. M. Prutt, Coupled Transcription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B. D. Hames and S. J. Higgins, eds.) p. 179-209, IRL Press, Oxford-Washington, 1984]

The antibiotics are added to exponentially growing cultures of tetracycline-susceptible E. coli at growth inhibitory concentrations. After 30 minutes, excess antibiotic is removed from the bacteria by centrifugation and the organism is resuspended in fresh growth medium. The ability of bacteria to resume growth is monitored. Washing of inhibited cells alleviates growth inhibition due to chlortetracycline, but not that caused by polymyxin. This reflects the different binding characteristics of the drugs. Chlortetracycline binds reversibly to bacterial ribosomes, while polymyxin remains tightly associated with its target, the cytoplasmic membrane, and continues to prevent bacterial growth even when excess antibiotic is removed.

In Vivo Antibacterial Evaluation (Table VII)

The therapeutic effects of tetracyclines are determined against acute lethal infections with various staphylococcal and E. coli strains. Female mice, strain CD-1 (Charles River Laboratories), 20±2 grams, are challenged by an intraperitoneal injection of sufficient bacteria (suspended in broth or hog mucin) to kill non-treated controls within 24-48 hours. Antibacterial agents, contained in 0.5 ml of 0.2% aqueous agar, are administered subcutaneously or orally 30 minutes after infection. When an oral dosing schedule is used, animals are deprived of food for 5 hours before and 2 hours after infection. Five mice are treated at each dose level. The 7 day survival ratios from 3 separate tests are pooled for calculation of median effective dose (ED50).

E. coli in Vitro Protein Translation System(Table VIII)

An in vitro, cell free, protein translation system using extracts from E. coli strain MRE600 (tetracycline sensitive) and a derivative of MRE600 containing the tetM determinant has been developed based on literature methods [J. M. Pratt, Coupled Transcription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B. D. Hames and S. J. Higgins, eds) p. 179-209, IRL Press, Oxford-Washington, 1984].

Using the systems described above, the novel tetracycline compounds of the present invention are tested for their ability to inhibit protein synthesis in vitro. Briefly, each 10 μl reaction contains S30 extract (a whole extract) made from either tetracycline sensitive cells or an isogenic tetracycline resistant (tetM) strain, low molecular weight components necessary for transcription and translation (i.e. ATP and GTP), a mix of 19 amino acids (no methionine), 35S labeled methionine, DNA template (either pBR322 or pUC119), and either DMSO (control) or the novel tetracycline compound to be tested (“Novel Tc”) dissolved in DMSO.

The reactions are incubated for 20 minutes at 37° C. Timing is initiated with the addition of the S30 extract, the lase component to be added. After 30 minutes, 2.5 μl of the reaction is removed and mixed with 0.5 ml of 1N NaOH to destroy RNA and tRNA. Two ml of 25% trichloroacetic acid is added and the mixture incubated at room temperature for 15 minutes. The trichloracetic acid precipitated material is collected on Whatman GF/C filters and washed with a solution of 10% trichloroacetic acid. The filters are dried and the retained radioactivity, representing incorporation of 35S-methionine into polypeptides, is counted using standard liquid scintillation methods.

The percent inhibition (P.I.) of protein synthesis is determined to be: P.I. = 100 - [ Retained  radioactivity  of  Novel  TC  containing  sample Retained  radioactivity  of  the  DMSO  control  reaction ] × 100
Testing Results

The claimed compounds exhibit antibacterial activity against a spectrum of tetracycline sensitive and resistant Gram-positive and Gram-negative bacteria, especially, strains of E. coli, S. aureus and E. faecalis, containing the tetM resistance determinants (Table I). Notable is 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline, as shown in Tables I and IV, which has good in vitro activity against tetracycline resistant strains containing the tetM resistance determinant (such as S. aureus UBMS 88-5, S. aureus UBMS 90-1 and 90-2, E. coli UBMS 89-1 and 90-4) and is equally as effective as minocycline against susceptible strains.

7-(Dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline demonstrates effective activity against minocycline susceptible strains including a variety of recently isolated bacteria from clinical sources (Table V). With the exception of some Proteus spp., 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline's activity is superior to that of minocycline against other isolates.

Protein synthesis, directed by cell-free extracts from the tetracycline susceptible strain MRE-600, are inhibited by tetracycline, minocycline and the 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline of this invention (Table 6). Protein synthesis, directed by cell-free extracts from strain MRE 600 (tetM), is resistant to tetracycline and minocycline, since 50% inhibition of protein synthesis required addition of approximately 5-fold more antibiotic than in extracts prepared from strain MRE 600 (Table VI). However, in contrast, 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline effectively inhibited protein synthesis in extracts prepared from either MRE 600 or MRE 600 (tetM) (Table VI). The evidence presented indicates that 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxy-tetracycline is an inhibitor of protein synthesis at the ribosome level. The ability of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline to inhibit bacterial growth almost certainly reflects directed inhibition of bacterial synthesis. If so, then it is expected, like other tetracyclines, to exhibit a bacteriostatic effect against susceptible bacteria.

7-(Dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline binds reversibly to its target (the ribosome) since bacterial growth resumed when the compound was removed from the cultures by washing of the organism. Therefore, the ability of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline to inhibit bacterial growth appears to be a direct consequence of its ability to inhibit protein synthesis at the ribosome level.

The enhanced activity (Table VII) of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline against tetracycline susceptible and resistant organisms (tetM) is also demonstrated in vivo in animals infected with S. aureus UBMS 90-1 and 90-2. The ED50's (Table VII) obtained for 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline are lower than those of minocycline.

The improved efficacy of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline is demonstrated by the in-vitro activity against isogenic strains into which the resistance determinants, such as tetM, were cloned (Tables I-IV); the inhibition of protein synthesis by tetM ribosomes (Table VI); and the in vivo activity against experimental infections caused by strains resistant to the tetracyclines, due to the presence of resistance determinants, such as tetM (Table VII).

As can be seen from Tables I-V, compounds of the invention may be used to prevent or control important veterinary diseases such as mastitis, diarrhea, urinary tract infections, skin infections, ear infections, wound infections and the like.

LEGEND FOR COMPOUNDS LETTER NAME A 7-(Dimethylamino)-9-(formylamino)-6-demethyl-6-de- oxytetracycline B 9-(Acetylamino)-7-(dimethylamino)-6-demethyl-6-de- oxytetracycline C 7-(Dimethylamino)-9-(dimethylamino)-6-demethyl-6-de- oxytetracycline D 7-(Diethylamino)-9-(formylamino)-6-demethyl-6-de- oxytetracycline disulfate E 9-(Acetylamino)-7-(diethylamino)-6-demethyl-6-de- oxytetracycline disulfate F 9-(Acetylamino)-7-(diethylamino)-6-demethyl-6-de- oxytetracycline G 9-(Formylamino)-7-iodo-6-demethyl-6-deoxytetracy- cline sulfate H 9-(Acetylamino)-7-iodo-6-demethyl-6-deoxytetracy- cline sulfate I 7-(Dimethylamino)-9-((trifluoroacetyl)amino]-g-de- methyl-6-deoxytetracycline sulfate J 7-(Dimethylamino)-9-([(phenylmethoxy)acetyl)- amino]-6-demethyl-6-deoxytetracycline K 9-[[(Acetyloxy)acetyl]amino)-7-(dimethylamino)-6- demethyl-6-deoxytetracycline L 7-(Dimethylamino)-9-[(hydroxyacetyl)amino]-6-de- methyl-6-deoxytetracycline M 9-[(Aminoacetyl)amino]-7-(dimethylamino)-6-demeth- yl-6-deoxytetracycline mono(trifluoroacetate) N [7S-(7α,10aα) ]-C(9-(Aminocarbonyl)-7-(dimethyl- amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11- tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]- oxoacetic acid ethyl ester O 7-(Dimethylamino)-6-demethyl-6-deoxytetracycline hydrochloride (minocycline hydrochloride) P 9-(Benzoylamino)-7-(dimethylamino)-6-demethyl-6- deoxytetracycline Q 7-(Dimethylamino)-9-[(4-methoxybenzoyl)amino)-6- demethyl-6-deoxytetracycline R 7-(Dimethylamino)-9-((2-methylbenzoyl)amino]-6-de- methyl-6-deoxytetracycline S 7-(Dimethylamino)-9-[(2-fluorobenzoyl)amino]-6-de- methyl-6-deoxytetracycline T 7-(Dimethylamino)-9-((pentafluorobenzoyl)amino]-6- demethyl-6-deoxytetracycline U 7-(Dimethylamino)-9-[[3-(trifluoromethyl)benzoyl)- amino]-6-demethyl-6-deoxytetracycline V 7-(Dimethylamino)-9-[(4-nitrobenzoyl)amino]-6-de- methyl-6-deoxytetracycline W 7-(Dimethylamino)-9-[[(4-dimethylamino)benzoyl)- amino)-6-demethyl-6-deoxytetracycline X 9-[(4-Aminobenzoyl)amino)-7-(dimethylamino)-6-de- methyl-6-deoxytetracycline sulfate Y 7-(Dimethylamino)-9-((2-furanylcarbonyl)amino)-6- demethyl-6-deoxytetracycline Z 7-(Dimethylamino)-9-[(2-thienylcarbonyl)amino]-6- demethyl-6-deoxytetracycline AA 7-(Dimethylamino)-9-[[(4-nitrophenyl)sulfonyl]- amino]-6-demethyl-6-deoxytetracycline BB 7-(Dimethylamino)-9-[(3-nitrophenyl)sulfonyl)- amino]-6-demethyl-6-deoxytetracycline CC 7-(Dimethylamino)-9-[(phenylsulfonyl)amino]-6-de- methyl-6-deoxytetracycline DD 7-(Dimethylamino)-9-[(2-thienylsulfonyl)amino)-6- demethyl-6-deoxytetracycline EE 9-[[(4-Chlorophenyl)sulfonyl]amino)-7-(dimethyl- amino)-6-demethyl-6-deoxytetracycline FF 7-(Dimethylamino)-9-[(methylsulfonyl)amino]-6-de- methyl-6-deoxytetracycline GG 9-[[[(2-Acetylamino)-4-methyl-5-thiazolyl]sul- fonyl]amino]-7-(dimethylamino)-6-demethyl-6-deoxy- tetracycline HH [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimeth- ylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,- 11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]car- bamic acid methyl ester II 7-(Dimethylamino)-9-[[(dimethylamino)acetyl]- amino]-6-demethyl-6-deoxytetracycline sulfate TC Tetracycline hydrochloride JJ [4S-(4alpha,12aalpha))-4,7-Bis(dimethylamino)-9- ([(dimethylamino)acetyl)amino]-1,4,4a,5,5a,6,11,- 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 2-naphthacenecarboxamide disulfate KK [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,- 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-di- oxo-2-naphthacenecarboxamide dihydrochloride LL [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,- 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 2-naphthacenecarboxamide MM [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1, 4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra- hydroxy-9-[[(methylamino)acetyl]amino]-1,11-dioxo- 2-naphthacenecarboxamide dihydrochloride NN [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octa- hydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naph- thacenyl)-4-morpholineacetamide dihydrochloride OO [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- CC(ethylamino)acetyl)amino]-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 2-naphthacenecarboxamide dihydrochloride PP [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(butylamino)acetyl]amino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride QQ [4S-(4alpha,12aalpha))-9[[(Cyclopropylamino)acet- yl)amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,- 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 2-naphthacenecarboxamide dihydrochloride RR [4S-(4alpha,12aalpha))-9-([(Diethylamino)acetyl)- amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,- 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 2-naphthacenecarboxamide dihydrochloride SS [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro- 1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacen- yl]-1-pyrrolidineacetamide dihydrochloride TT [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahy- droxy-9-[[[(2-methylpropyl)amino]acetyl]amino)-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride UU [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octa- hydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphtha- cenyl)-1-piperidineacetamide dihydrochloride VV [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octa- hydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naph- thacenyl]-1H-imidazole-1-acetamide dihydrochloride WW [4S-(4alpha,12aalpha)]-4,7-bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy- 1,11-dioxo-9-[[(propylamino)acetyl]amino]-2- naphthacenecarboxamide dihydrochloride XX [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino(-9- [[2-(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide dihydrochloride YY [4S-(4alpha,12aalpha))-4,7-Bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahy- droxy-9-[[2-(methylamino)-1-oxopropyl]amino]-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride ZZ [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[4-(dimethylamino)-1-oxobutyl]amino]-1,4,4a,5, 5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2-naphthacenecarboxamide dihydrochloride AAA [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy- dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naph- thacenyl)-alpha-methyl-1-pyrrolidineacetamide dihydrochloride BBB [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(hexylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2- naphthacenecarboxamide dihydrochloride CCC [4S-(4alpha,12aalpha)]-9-[[(Butylmethylamino)- acetyl]amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a, 6,11,12a-octahydro-3,10-12,12a-tetrahydroxy-1,11- dioxo-2-naphthacenecarboxamide dihydrochloride DDD [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4 4a,5,5a,6,11,12a-octahydro-3,10-12,12a-tetrahy- droxy-1,11-dioxo-9-[[(pentylamino)acetyl]amino)-2- naphthacenecarboxamide dihydrochloride EEE [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4, 4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahy- droxy-1,11-dioxo-9-[[[(phenylmethyl)amino]acetyl]- amino]-2-naphthacenecarboxamide dihydrochloride FFF [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide GGG [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- [[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- N-(4-morpholinylmethyl)-2-naphthacenecarboxamide HHH [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9- ([(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- N-(1-piperadinylmethyl)-2-naphthacenecarboxamide III [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino)-4,7- bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahy- dro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naph- thacenecarboxamide dihydrochloride JJJ [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)- amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 2-naphthacenecarboxamide hydrobromide KKK [7S-(7alpha,10aalpha]-N-[2-[[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy- dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphtha- cenyl)amino]-2-oxoethyl]glycine LLL (7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7- bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy- dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphtha- cenyl]-1-azetidineacetamide MMM [4S-(4alpha,12aalpha)]-g-[[(Cyclobutylamino)acet- yl]amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11, 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo- 2-naphthacenecarboxamide

TABLE I ANTIBACTERIAL ACTIVITY OF 9-(ACYLAMINO)-7-(SUBSTITUTED)-6-DEMETHYL-6- DEOXYTETRACYCLINES MIC (μg/ml) COMPOUND ORGANISM A B C D E F G H I S. aureus UBMS 88-5 (tetM) 0.06 0.12 0.12 0.25 4 0.5 1 1 16 S. aureus UBMS 88-4 (Sensitive) 0.015 ≦0.06 0.03 0.12 0.5 0.25 <0.015 0.25 8 S. aureus UBMS 90-1 (tetM) 0.06 ND 0.5 0.5 8 2 4 1 16 S. aureus UBMS 90-2 (tetM) 0.03 ND 0.12 0.12 2 0.5 0.5 0.5 16 S. aureus UBMS 90-3 (Sensitive) ≦0.015 ND 0.03 0.06 0.5 0.12 0.03 0.12 4 S. aureus UBMS 88-7 (tetK) 2 4 0.25 2 4 2 16 16 16 S. aureus IVES 2943 (meth. 4 64 1 4 8 2 32 32 ND resistant) S. aureus IVES 1983 (meth. 8 ND 1 4 16 4 32 32 32 resistant) S. aureus ATCC 29213 (Sensitive) ≦0.015 0.12 ≦0.015 ≦0.015 ≦0.015 ≦0.015 ND 0.22 1 S. aureus Smith (Sensitive) ≦0.015 0.12 0.03 0.03 0.5 0.12 0.03 0.12 8 S. haemolyticus AVAH 88-3 0.03 ND 0.12 ND 8 2 0.06 2 0.5 E. faecalis 12201 0.12 0.5 0.5 1 16 4 16 2 16 E. faecalis ATCC 29212 ≦0.015 0.12 0.06 0.12 2.0 0.25 0.25 0.25 8 E. coli UBMS 88-1 (tetB) 32 >128 16 >32 >32 >32 >32 >128 >32 E. coli UBMS 88-2 (Sensitive) 0.12 2 0.25 0.5 >32 32 1 >128 32 E. coli UBMS 89-1 (tetM) 0.12 ND 1 ND 32 4 1 128 32 E. coli UBMS 89-2 (Sensitive) 0.12 ND 0.5 0.5 >32 32 1 16 32 E. coli ATCC 25922 0.06 2 0.25 0.5 32 4 0.5 16 32 MIC (μg/ml) COMPOUND ORGGANISM J K L M N O HH II S. aureus UBMS 88-5 (tetM) 4 0.25 4 1 32 2 0.25 0.12 S. aureus UBMS 88-4 (Sensitive) 2 0.12 4 1 2 ≦0.015 0.03 0.06 S. aureus UBMS 90-1 (tetM) 4 0.25 8 2 >32 4 1 0.25 S. aureus UBMS 90-2 (tetM) 2 0.06 2 0.5 32 2 0.25 0.06 S. aureus UBMS 90-3 (Sensitive) 0.5 0.03 1 0.5 1 ≦0.015 0.03 0.06 S. aureus UBMS 88-7 (tetK) 2 32 >32 >32 8 0.06 0.5 0.06 S. aureus IVES 2943 (meth. 4 32 >32 >32 32 1 2 1 resistant) S. aureus IVES 1983 (meth. 4 32 >32 >32 >32 1 2 1 resistant) S. aureus ATCC 29213 (Sensitive) 0.06 ≦0.015 0.5 0.5 0.25 ≦0.015 ≦0.015 0.03 S. aureus Smith (Sensitive) 0.5 ≦0.015 0.5 1 2 ≦0.015 0.03 0.12 S. haemolyticus AVAH 88-3 4 0.5 16 1 4 0.03 0.25 0.25 E. faecalis 12201 2 0.25 4 0.25 32 4 2 0.12 E. faecalis ATCC 29212 4 0.06 2 0.25 32 0.5 0.25 0.03 E. coli UBMS 88-1 (tetB) >32 16 >32 2 >32 8 16 0.25 E. coli UBMS 88-2 (Sensitive) >32 4 >32 2 >32 0.5 ND ND E. coli UBMS 89-1 (tetM) >32 1 >32 2 >32 16 4 0.12 E. coli UBMS 89-2 (Sensitive) >32 8 >32 2 >32 0.5 4 0.25 E. coli ATCC 25922 32 4 32 2 32 0.25 2 0.12

TABLE II ANTIBACTERIAL ACTIVITY OF 9-(AROYLAMINO) AND 9-(HETEROYLAMINO)-7- (SUBSTITUTED)-6-DEMETHYL-6-DEOXYTETRACYCLINES MIC (μg/ml) COMPOUND ORGANISM P Q R S T U V W X Y Z O S. aureus UBMS 88-5 (tetM) 4 8 4 2 4 1 2 32 8 16 8 2 S. aureus UBMS 88-4 (Sensitive) 4 8 2 2 4 0.5 2 8 1 4 8 ≧0.015 S. aureus UBMS 90-1 (tetM) 4 8 8 4 4 1 2 16 16 32 4 4 S. aureus UBMS 90-2 (tetM) 4 8 2 1 2 1 1 8 8 8 4 2 S. aureus UBMS 90-3 (Sensitive) 1 4 1 1 2 0.5 0.5 8 1 2 2 ≦0.015 S. aureus UBMS 88-7 (tetK) 8 16 4 8 4 1 4 16 8 >32 32 0.06 S. aureus IVES 2943 (meth. resistant) 16 8 4 8 4 1 4 8 >32 >32 32 4 S. aureus IVES 1983 (meth. resistant) 8 16 8 4 4 1 8 8 >32 >32 32 4 S. aureus ATCC 29213 (Sensitive) 0.25 1 0.12 0.5 1 0.5 0.25 2 0.5 0.5 0.5 ≦0.015 S. aureus Smith (Sensitive) 1 4 1 1 4 1 0.5 4 1 2 2 ≦0.015 S. haemolyticus AVAH 88-3 4 8 8 4 4 1 4 16 8 >32 8 0.03 E. faecalis 12201 8 8 8 4 4 1 4 16 32 32 8 4 E. faecalis ATCC 29212 4 8 2 4 4 1 4 8 8 8 8 0.5 E. coli UBMS 88-1 (tetB) >32 >32 2 >32 >32 >32 >32 >32 >32 >32 >32 8 E. coli UBMS 88-2 (Sensitive) >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 0.5 E. coli UBMS 89-1 (tetM) ND ND ND ND ND >32 >32 >32 >32 >32 >32 16 E. coli UBMS 89-2 (Sensitive) >32 >32 >32 >32 >32 ≧32 >32 >32 >32 >32 >32 0.5 E. coli ATCC 25922 >32 >32 >32 >32 >32 ≧32 >32 >32 >32 >32 32 0.25

TABLE III ANTIBACTERIAL ACTIVITY OF 9-(SULFONYLAMINO)-7-(SUBSTITUTED)- 6-DEMETHYL-6-DEOXYTETRACYCLINES MIC (μg/ml) COMPOUND ORGANISM AA BB CC DD EE FF GG O S. aureus UBMS 88-5 (tetM) 0.12 ND 4 0.5 0.12 0.25 16 4 S. aureus UBMS 88-4 (Sensitive) 0.12 1 0.03 0.5 0.12 0.25 4 0.03 S. aureus UBMS 90-1 (tetM) 0.5 2 4 1 0.25 0.25 32 2 S. aureus UBMS 90-2 (tetM) 0.12 0.5 0.06 0.25 0.12 0.06 4 1 S. aureus UBMS 90-3 (Sensitive) 0.06 0.12 4 0.25 0.12 0.12 2 ≦0.015 S. aureus UBMS 88-7 (tetK) 2 4 4 2 1 8 32 0.06 S. aureus IVES 2943 (meth. resistant) 4 4 4 4 0.5 16 >32 2 S. aureus IVES 1983 (meth. resistant) 8 8 4 4 1 16 32 1 S. aureus ATCC 29213 (Sensitive) 0.12 0.06 ≦0.015 0.03 0.03 0.03 0.5 ≦0.015 S. aureus Smith (Sensitive) 0.12 0.25 4 0.03 0.12 0.12 2 ≦0.015 S. haemolyticus AVAH 88-3 2 4 4 2 ND ND ND 0.06 E. faecalis 12201 ND ND ND ND ND ND ND 8 E. faecalis ATCC 29212 0.12 0.12 0.06 0.25 0.06 0.06 1 0.5 E. coli UBMS 88-1 (tetB) 16 >32 16 32 >32 8 >32 16 E. coli UBMS 88-2 (Sensitive) 8 4 8 8 >32 2 >32 0.5 E. coli UBMS 89-1 (tetM) 4 ND ND ND ND ND 32 16 E. coli UBMS 89-2 (Sensitive) 16 16 16 16 >32 2 >32 0.5 E. coli ATCC 25922 4 2 2 4 >32 2 >32 0.5

TABLE IA ANTIBACTERIAL ACTIVITY OF 9-(ACYLAMINO)-7-(SUBSTITUTED)- 6-DEMETHYL-6-DEOXYTETRACYCLINES JJ KK LL MM NN OO PP QQ RR SS E. coli UBMS 88-1 TetB 0.25 0.25 0.25 1 >32 1 0.5 4 1 0.25 E. coli J3272 Tet sens. 0.25 0.12 0.12 1 >32 1 0.5 2 1 0.25 E. coli MC4100 Tet sens. NT NT NT NT NT NT NT NT NT NT E. coli MC4100 TetB 0.25 0.25 0.25 1 >32 1 0.5 2 1 0.25 E. coli PRP1 TetA 2 1 1 16 >32 2 1 32 2 0.5 E. coli J3272 TetC 1 1 0.5 8 >32 2 0.5 8 1 0.25 E. coli UBMS 89-1 TetM 0.25 0.12 0.12 1 32 1 0.25 1 0.25 0.12 E. coli UBMS 89-2 Tet Sens. 0.25 0.25 0.12 1 >32 1 0.5 2 1 0.25 E. coli J2175 0.25 0.25 0.12 1 >32 1 0.25 2 1 0.25 E. coli BAJ9003 0.03 0.03 NG 0.25 0.5 0.12 0.12 0.25 0.06 ≦0.015 E. coli UBMS 90-4 TetM 0.25 0.25 0.25 CONT CONT 0.5 0.25 2 0.5 0.25 E. coli UBMS 90-5 0.25 0.25 0.12 1 >32 1 0.5 2 1 0.25 E. coli #311 (MP) 0.25 0.25 0.12 1 >32 1 0.25 2 0.5 0.12 E. coli ATCC 25922 0.25 0.25 0.12 1 >32 1 0.25 2 0.5 0.25 E. coli J3272 TetD 0.12 0.12 0.06 0.05 32 0.5 0.25 2 0.25 0.12 S. mariescens FDOR 8733 4 2 2 16 >32 8 2 >32 4 2 X. maltophilia NEMC 87210 0.5 0.25 0.25 8 32 2 0.5 2 0.25 0.5 Ps. acruginosa ATCC 27853 8 4 4 16 >32 16 16 >32 32 16 S. aureus NEMC 8769/89-4 0.06 0.06 ≦0.015 0.5 0.5 0.5 0.12 0.12 0.06 0.03 S. aureus UBMS 88-4 0.25 0.12 0.06 0.5 2 1 0.25 0.5 0.25 0.12 S. aureus UBMS 88-5 TetM 0.25 0.25 0.12 0.5 4 1 0.5 0.5 0.25 S. aureus UBMS 88-7 TetK 1 0.25 0.5 16 32 8 2 4 0.5 0.5 S. aureus UBMS 90-1 TetM 0.25 0.25 0.12 1 4 1 0.5 0.5 0.25 0.12 S. aureus UBMS 90-3 0.12 0.03 0.06 0.5 2 0.5 0.25 0.5 0.25 0.12 S. aureus UBMS 90-2 TetM 0.25 0.12 0.12 0.5 2 0.5 0.5 0.5 0.25 0.12 S. aureus IVES 2943 2 1 1 32 >32 8 2 16 1 1 S. aureus ROSE (MP) 2 1 1 32 >32 8 2 16 1 1 S. aureus SMITH (MP) 0.12 0.06 0.06 0.5 2 0.5 0.12 0.25 0.25 0.12 S. aureus IVES 1983 2 1 1 16 >32 8 2 8 0.25 0.5 S. aureus ATCC 29213 0.03 ≦0.015 0.06 1 2 1 0.25 0.5 0.12 0.12 S. hemolyticus AVHAH 88-3 0.25 0.12 0.12 1 32 1 0.25 2 0.5 0.25 Enterococcus 12201 0.12 0.12 0.06 0.25 2 0.25 0.12 0.5 0.12 0.12 E. faecalis ATCC 29212 0.12 0.06 0.06 0.25 2 0.25 0.12 0.25 0.12 0.12 TT UU VV WW XX YY ZZ AAA BBB CCC DDD E. coli UBMS 88-1 TetB 0.5 0.5 >32 0.25 0.5 0.5 >32 0.5 0.5 1 0.5 E. coli J3272 Tet sens. 0.5 0.5 >32 0.25 0.5 0.5 NT NT NT NT NT E. coli MC4100 Tet sens. NT NT NT NT NT NT 2 0.12 0.25 0.25 0.12 E. coli MC4100 TetB 0.5 0.5 >32 0.25 1 0.5 >32 0.5 0.5 2 0.5 E. coli PRP1 TetA 2 1 >32 1 1 2 >32 0.5 0.5 2 1 E. coli J3272 TetC 0.5 0.5 >32 0.25 1 1 32 0.5 0.5 1 0.5 E. coli UBMS 89-1 TetM 0.25 0.12 >32 0.25 0.12 0.5 32 0.12 0.25 0.25 0.25 E. coli UBMS 89-2 Tet Sens. 0.5 0.5 >32 0.25 0.5 0.5 16 0.5 0.25 2 0.5 E. coli J2175 0.5 0.5 >32 0.25 0.5 0.5 16 0.5 0.25 2 0.5 E. coli BAJ9003 0.06 0.06 1 0.06 0.06 0.06 1 0.06 0.06 0.12 0.12 E. coli UBMS 90-4 TetM 0.5 0.5 >32 0.25 0.5 0.5 16 0.5 0.25 1 0.5 E. coli UBMS 90-5 0.5 0.5 >32 0.25 0.5 0.5 16 0.5 0.25 2 0.5 E. coli #311 (MP) 0.5 0.25 >32 0.25 0.5 0.5 16 0.25 0.5 1 0.5 E. coli ATCC 25922 0.5 0.25 >32 0.25 0.5 0.5 8 0.25 0.12 1 0.5 E. coli J3272 TetD 0.12 0.25 >32 0.12 0.25 0.25 4 0.12 0.12 0.5 0.25 S. mariescens FDOR 8733 4 4 >32 2 4 8 >32 4 4 16 8 X. maltophilia NEMC 87210 0.5 0.12 >32 0.5 0.5 4 32 0.5 4 0.25 0.5 Ps. acruginosa ATCC 27853 16 32 >32 8 32 16 >32 >32 16 >32 32 S. aureus NEMC 8769/89-4 0.03 0.06 4 0.06 0.12 0.12 1 0.12 0.06 0.12 0.25 S. aureus UBMS 88-4 0.25 0.25 8 0.25 0.25 0.5 2 0.25 0.25 0.5 0.5 S. aureus UBMS 88-5 TetM 0.25 0.25 32 0.25 0.25 0.5 8 0.25 0.5 0.5 0.5 S. aureus UBMS 88-7 TetK 2 0.25 32 1 1 4 16 0.5 2 1 2 S. aureus UBMS 90-1 TetM 0.25 0.25 32 0.12 0.25 0.25 8 0.5 0.25 1 1 S. aureus UBMS 90-3 0.12 0.12 4 0.12 0.25 0.12 2 0.25 0.06 0.25 0.5 S. aureus UBMS 90-2 TetM 0.25 0.12 16 0.25 0.25 0.25 4 0.25 0.25 0.25 0.5 S. aureus IVES 2943 2 0.25 >32 2 1 8 >32 0.5 4 1 4 S. aureus ROSE (MP) 2 0.5 >32 2 1 8 >32 2 16 2 4 S. aureus SMITH (MP) 0.12 0.12 4 0.12 0.25 0.25 2 0.25 0.12 0.5 0.25 S. aureus IVES 1983 2 0.5 >32 2 1 4 >32 0.5 4 1 4 S. aureus ATCC 29213 0.25 0.12 8 0.25 0.25 0.5 2 0.25 0.25 0.5 1 S. hemolyticus AVHAH 88-3 0.5 0.12 >32 0.25 0.5 0.5 8 0.5 0.5 0.5 0.5 Enterococcus 12201 0.25 0.12 4 0.12 0.12 0.25 8 0.12 0.25 0.25 0.25 E. faecalis ATCC 29212 0.25 0.06 4 0.25 0.12 0.12 4 0.12 0.12 0.12 0.25 EEE FFF GGG HHH III JJJ KKK LLL MMM E. coli UBMS 88-1 TetB 2 0.25 0.25 0.25 >32 >32 >32 0.5 0.5 E. coli J3272 Tet sens. NT NT NT NT 16 >32 >32 0.25 0.06 E. coli MC4100 Tet sens. 0.5 0.06 0.06 0.12 NT NT 32 NT NT E. coli MC4100 TetB 4 0.25 0.25 0.25 >32 >32 >32 0.5 0.25 E. coli PRP1 TetA 4 2 1 2 >32 >32 >32 1 4 E. coli J3272 TetC 2 1 1 0.5 >32 >32 >32 0.5 0.5 E. coli UBMS 89-1 TetM 0.5 0.12 0.12 0.25 4 32 >32 0.25 0.25 E. coli UBMS 89-2 Tet Sens. 4 0.25 0.25 0.25 32 >32 >32 0.5 0.5 E. coli J2175 4 0.25 0.25 0.25 32 >32 >32 0.25 0.25 E. coli BAJ9003 0.25 ≧0.015 0.03 0.03 0.25 4 16 0.06 0.03 E. coli UBMS 90-4 TetM 0.5 0.12 0.25 0.25 — >32 >32 0.25 0.25 E. coli UBMS 90-5 0.5 0.25 0.25 0.25 16 >32 >32 0.25 0.5 E. coli #311 (MP) 0.5 0.25 0.25 0.25 8 >32 >32 0.25 0.25 E. coli ATCC 25922 0.5 0.12 0.12 0.25 16 >32 >32 0.25 0.25 E. coli J3272 TetD 0.5 0.12 0.12 0.12 32 >32 >32 0.12 0.12 S. mariescens FDOR 8733 4 4 4 4 >32 >32 >32 2 8 X. maltophilia NEMC 87210 1 0.25 0.5 0.5 4 16 >32 1 0.5 Ps. acruginosa ATCC 27853 32 8 8 8 >32 >32 >32 8 32 S. aureus NEMC 8769/89-4 0.12 0.25 0.25 0.25 0.12 4 32 0.12 0.5 S. aureus UBMS 88-4 0.25 0.12 0.12 0.25 0.5 8 32 0.25 0.25 S. aureus UBMS 88-5 TetM 0.5 0.12 0.12 0.25 1 8 >32 0.25 0.25 S. aureus UBMS 88-7 TetK 2 1 1 0.5 2 16 >32 2 4 S. aureus UBMS 90-1 TetM 0.5 0.12 0.25 0.25 1 16 >32 0.25 0.5 S. aureus UBMS 90-3 0.25 0.12 0.12 0.12 0.5 2 16 0.12 0.12 S. aureus UBMS 90-2 TetM 0.25 0.12 0.12 0.12 0.5 8 32 0.25 0.25 S. aureus IVES 2943 2 2 2 2 4 32 >32 2 4 S. aureus ROSE (MP) 8 2 2 2 8 >32 >32 2 8 S. aureus SMITH (MP) 0.25 0.12 0.12 0.12 0.5 4 16 0.25 0.25 S. aureus IVES 1983 2 2 2 2 4 32 >32 2 4 S. aureus ATCC 29213 0.5 0.12 0.25 0.25 0.5 4 32 0.25 0.25 S. hemolyticus AVHAH 88-3 2 0.25 0.5 0.5 2 16 >32 0.25 0.24 Enterococcus 12201 0.25 0.12 0.12 0.12 1 16 >32 0.25 0.24 E. faecalis ATCC 29212 0.25 0.06 0.06 0.06 0.5 16 16 0.25 0.25 NG = No Growth CONT = Contaminated NT = Not Tested

TABLE IV Susceptibility of Sensitive and Resistant (tetM) Organisms to Tetracyclines MIC (μg/ml) Organisms A O TC E. coli UBMS 88-2 (Sensitive) 0.12 0.5 ND E. coli UBMS 90-4 (tetM) 1 64 64 S. aureus UBMS 88-4 (Sensitive) <0.015 0.03 0.12 S. aureus UBMS 88-5 (tetM) 0.03 2 32 S. aureus UBMS 90-3 (Sensitive) <0.015 0.03 0.12 S. aureus UBMS 90-1 (tetM) 0.12 4 32 N. gonorrhoeae IL 611 (Sensitive) 0.06 0.5 ND N. gonorrhoeae 6418 (tetM) 1 >32 >32 E. faecalis UBMS 90-6 (tetM) 0.12 8 32 E. faecalis UBMS 90-7 (tetM) 0.5 8 32

TABLE V In vitro Activity of Compounds A and O Against Clinical Isolates MIC (μg/ml)+ No. Anti- Organism Tested biotic Range MIC50 MIC90 Neisseria  (9) A   0.015-1.00 0.03 1.00 gonorrhoeae O   0.03->32.00 0.25 >32.00 Haemophilus (18) A <0.008-0.06 0.06 0.06 influenzae O   0.06-0.25 0.12 0.25 Enterococcus (14) A <0.015-2.00 0.12 1.00 faecalis O <0.015-16.00 4.00 16.00 Enterococcus (11) A <0.015-2.00 0.06 2.00 faecium O <0.015-16.00 8.00 16.00 Escherichia coli (10) A   0.06->32.00 0.25 >32.00 O   0.12-32.00 0.25 16.00 Klebsiella (10) A   0.25->32.00 0.50 0.50 pneumoniae O   1.00->32.00 1.00 4.00 Proteus spp.  (9) A   0.50->32.00 2.00 >32.00 indole+ O   1.00->32.00 16.00 >32.00 Bacteroides spp. (15) A >0.15-4.00   0.25 2.00 O >0.15-16.00 1.00 4.00 In Vitro Activity of KK and Comparative Antibiotics vs Recent Clinical and Agricultural Isolates MIC (μg/ml) [No. Organism Tested] KK O TC Staphylococcus aureus, [15] 0.12-2   0.06-4 0.25->64 methicillin-resistant Staphylococcus aureus, [15] 0.12-0.25   0.03-0.12 0.12-1 methicillin-susceptible Staphylococcus [16] 0.12-8   0.03-1 0.12->64 Coagulase-negative, methicillin-susceptible Enterococcus faecalis [10] 0.015-0.12   0.03-16 0.12-64 Enterococcus faecium [10] 0.03-0.12   0.03-16 0.12-64 Enterococcus spp.  [8] 0.015-0.06   0.03-16 0.12->64 Vancomycin-resistant Streptococcus pyogenes [10] 0.06-0.12   0.03-2 0.12-16 Streptococcus agalactiae [10] 0.06-0.25   0.12-16 0.25-64 Streptococcus [10] 0.03-0.25   0.06-0.5 0.12-2 pneumoniae Listeria monocytogenes  [8] 0.06-0.12   0.015-0.03 0.12-0.5 Escherichia coli [30] 0.12-4   0.25-32 0.5->64 (Clinical) Escherichia coli [15] 0.12-4   1-16 2->64 (Agricultural) Shigella spp. [14] 0.06-0.5   0.25-8 0.25->64 Kiebsiella pneumoniae [10] 0.25-8   0.5-8 0.5->64 Klebsiella oxytoca [10] 0.5-1   0.5-4 0.5-1 Citrobacter freundii [10] 0.25-8   0.03-32 0.5-16 Citrobacter diversus [10] 0.25-1   0.25-4 0.5-4 Salmonella spp. [11] 0.25-0.5   0.5-16 0.5->64 (Clinical) Salmonella cholerasuis [15] 0.5-16   2->64 1->64 (Agricultural) Serratia mercescens [10] 2-8   1-8 8->64 Enterobacter cloacae [10] 0.5-1   0.25-4 0.5-2 Enterobacter aerogenes [10] 0.5-1   0.5-1 0.5-1 Providencia spp. [13] 2-8   4->64 1->64 Proteus mirabilis [26] 1-32   1-32 0.5-64 Proteus vulgaris [18] 0.5-4   0.5-16 0.25-64 Morganella morganii [16] 0.5-4   0.25-32 0.25->64 Pseudomonas aeruginosa [10] 1-16   1-16 2-32 Xanthomonas maltophilia [10] 0.5-2   0.12-1 8-16 Moraxella catarrhalis [18] 0.06-0.12   0.03-0.12 0.06-0.5 Neisseria gonorrhoeae [14] 0.25-1   0.5-64 1->64 Haemophilus influenzae [15] 0.5-2   0.5-2 1-32 Pasturella multocida [17] 0.03-0.25   0.015-4 0.06-16 (Agricultural & Clinical) Bordetella [10] 0.12   0.06-0.12 0.12-0.25 bronchiseptica (Agricultural) Bacteroides fragilis [11] 0.06-0.2 <0.008-16 0.25->64 Bacertoides fragilis [10] 0.06-2 <0.008-4 0.25-32 group Bacteroides spp.  [9] 0.03-1   0.03-16 0.25->64 Clostridium difficile [12] 0.03   0.015-16 0.12-32 Clostridium perfringens [16] 0.03-1 >0.008-16 0.015-16 Clostridium spp.  [9] 0.015-0.12 <0.008-16 0.015-64 Anaerobic Gram (+) [15] 0.015-0.06   0.05-8 4->64 Cocci +MIC50 = minimum concentration required to inhibit 50% of strains tested. MIC90 = minimum concentration required to inhibit 90% of strains tested

TABLE VI Inhibition of Protein Synthesis Directed by E. coli Cell-free Ribosomes with Tetracyclines IC50 (μg/ml)+ Antibiotic TC Sensitive Host Tet M Host Tetracycline 0.6 2.0 Compound O 0.4 2.0 Compound A <0.3 0.4 +Concentration of antibiotic required to inhibit protein synthesis by 50% compared to a drug-free control

TABLE VII In vivo Protective Activity of Compounds A and O in Mice Infected with Staphylococci Containing the tetM Determinant Organism Compound ED50 (mg/kg)+ S. aureus UBMS 90-1 A 0.22 O 1.7 S. aureus UBMS 90-2 A 0.49 O 3.0 In Vitro Protective Activity in Mice Compounds (ED50 (mg/kg) Route of Antibiotic Organism Administration JJ KK LL PP RR SS TT S. aureus SMITH (sens) Oral 9.6  8-16 4-8 >16 8-16 8-16 8-16 S. aureus SMITH (sens) Intraveneous 0.61 0.68 0.25-0.5  1-2 — 1-2  1-2  S. aureus SMITH (sens) Subcutaneous 0.66 — — — — — — Escherichia coli Intraveneous — 2.49 — — — — — UBMS 90-4 (Tet-M) Route of Antibiotic Organism Administration BBB WW XX YY AAA DDD EEE O S. aureus SMITH (sens) Oral 4-8 >16 8-16 >16 >16 8-16 8-16 0.74 S. aureus SMITH (sens) Intraveneous 1.8 0.82 0.5-1   0.5-1 — — — 0.37 S. aureus SMITH (sens) Subcutaneous — — — — — — — — Escherichia coli Intraveneous — — — — — — — >32 UBMS 90-4 (Tet-M) +Median effective dose protecting 50% of the infected mice, single subcutaneous dosing.

TABLE VIII InVitro Transcription and Protein Translation Sensitivity to Tetracycline Compounds COMPOUND % INHIBITION Organism Concentration Wild Type S30 TetM S30 KK 1.0 mg/ml 92 95 0.5 mg/ml 90 96 0.25 mg/ml 89 93 0.12 mg/ml 84 93 0.06 mg/ml 82 89 0.03 mg/ml 81 75 MM 1.0 mg/ml 99 99 0.2 mg/ml 98 97 0.06 mg/ml 95 92 OO 1.0 mg/ml 99 99 0.2 mg/ml 97 95 0.06 mg/ml 94 87 QQ 1.0 mg/ml 99 99 0.2 mg/ml 97 95 0.06 mg/ml 92 85 RR 1.0 mg/ml 99 99 0.2 mg/ml 97 97 0.06 mg/ml 93 90 VV 1.0 mg/ml 99 98 0.2 mg/ml 93 92 0.06 mg/ml 91 79 WW 1.0 mg/ml 99 98 0.2 mg/ml 99 97 0.06 mg/ml 93 88 XX 1.0 mg/ml 98 97 0.2 mg/ml 96 89 0.06 mg/ml 85 78 Minocycline 1.0 mg/ml 98 68 0.2 mg/ml 89 43 0.06 mg/ml 78  0

When the compounds are employed as antibacterials, they can be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

An effective amount of compound from 2.0 mg/kg of body weight to 100.0 mg/kg of body weight should be administered one to five times per day via any typical route of administration including but not limited to oral, parenteral, (including subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques), topical or rectal, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.

The invention will be more fully described in conjunction with the following specific examples which are not to be construed as limiting the scope of the invention.

EXAMPLE 1 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

To a stirred ice bath cooled solution of 0.444 g of [4S-(4α,12aα)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Pat. No. 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.101 g of sodium nitrate. The mixture is stirred in the cold for 45 minutes followed by the dropwise addition to 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.6 g of the desired product as a solid.

MS(FAB): m/z 503(M+H) and 601(M+H2SO4+H).

EXAMPLE 2 [4S-(4α,12aα)]-9-Amino-4,7-bis(dimethylamino)-1,4a,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)

A mixture of 2.0 g of product from Example 1 in 20 ml of 2-methoxyethanol is stirred for 10 minutes and filtered. The filtrate is shaken, in a pressure bottle, with 1.0 g of 10% palladium-on-carbon and 5 ml of 2N sulfuric acid, under 30 lbs. of hydrogen pressure, for 1 hour. The reaction mixture is filtered and the filtrate concentrated in vacuo to half volume. The solution is poured into 100 ml of diethyl ether, the solid collected, washed with diethyl ether and dried to give 1.6 g of the desired product as a solid.

MS(FAB): m/z 473 (M+H).

EXAMPLE 3 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-1,11-dioxo-2-naphthacenecarboxamide

To a stirring 0° C. solution of 3.0 g of product from Example 2, 0.451 g of anhydrous sodium acetate and ml of 98% formic acid is added, dropwise, 7.4 ml of acetic anhydride. The reaction is stirred at 0° C. for 10 minutes followed by stirring at room temperature for 1 hour. The mixture is poured into 500 ml of diethyl ether and the precipitate collected. The solid is washed with diethyl ether and dried to give 2.9 g of the desired product.

MS(FAB): m/z 501 (M+H).

EXAMPLE 4 [4S-(4α,12aα)],4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a solution of 3.5 g of product from Example 3 in 150 ml of distilled water is added sufficient 0.75N sulfuric acid to bring the reaction solution of pH 3.6. The solution is lyophilized to give 3.6 g of the desired salt.

MS(FAB): m/z 501 (M+H).

EXAMPLE 5 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono-hydrochloride

To a solution of 3.5 g of product from Example 3 in 150 ml of distilled water is added sufficient 0.75N hydrochloric acid to bring the reaction solution of pH 3.6. The solution is lyophilized to give 3.6 g of the desired salt.

MS(FAB): m/z 501 (M+H).

EXAMPLE 6 [4S-(4α,12aα)]-9-(Acetylamino)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-1,11-dioxo-2-naphthacenecarboxamide

To a stirring solution of 0.468 g of product from Example 2 in 5 ml of water is added 0.50 g of sodium acetate and 0.2 ml of acetic anhydride. The reaction is stirred at room temperature for 10 minutes followed by the addition of 0.2 ml of concentrated ammonium hydroxide. After stirring 5 hours at room temperature, the reaction is treated with 0.5 ml of concentrated sulfuric acid. The reaction solution is extracted with 4 portions of n-butyl alcohol and the aqueous layer is concentrated in vacuo to dryness. The residue is triturated with 20 ml of methyl alcohol, filtered and the organic layer is concentrated in vacuo to give 0.35 g of the desired product.

MS(FAB): m/z 515 (M+H).

EXAMPLE 7 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-1,11-dioxo-9-[(trifluoroacetyl)amino]-2-naphthacenecarboxamide sulfate

A mixture of 0.20 g of product from Example 2 and 3.0 ml of trifluoroacetic anhydride is stirred at room temperature for 6 hours. The reaction liquid is decanted from the solid residue. The solid is dried, dissolved in 10 ml of methyl alcohol, stirred for 20 minutes and the mixture is poured into 100 ml of diethyl ether. The solid is collected and dried to give 0.16 g of the desired product.

MS(FAB): m/z 569 (M+H).

EXAMPLE 8 [4S-(4α,12aα)]-7-(Diethylamino)-4-(dimethylamino)-1,4o4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 9-nitro-1,11-dioxo-2-naphthacene-carboxamide sulfate (1:2)

To a stirred ice cooled solution of 0.660 g of [4S-(4α,12aα)]-7-(diethylamino)-4-(dimethylamino)-1,4a,-5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,-11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Pat. No. 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.151 g of sodium nitrate. The mixture is stirred in the cold followed by dropwise addition to 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.8 g of the desired product as a solid.

MS(FAB): m/z 531(M+H) and 629(M+H2SO4+H).

EXAMPLE 9 [4S-(4α,12aα)]-9-Amino-7-(diethylamino)-4-(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12 a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2)

The title compound is prepared by the procedure of Example 2, using 0.82 g of product from Example 8, to give 0.65 g of the desired product as a solid. 1H NMR (CD3SOCD3): δ 4.25(s,1H,4-H) and 7.27(s,1H,8-H).

MS(FAB): m/z 501(M+H) and 599 (M+H2SO4+H).

EXAMPLE 10 [4S-(4α,12aα)]-7-(Diethylamino)-4-(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2)

To a solution of 0.238 g of product from Example 9 in 6 ml of formic acid is added 0.035 g of sodium acetate and 0.75 ml of acetic anhydride. The reaction mixture is stirred at room temperature for 1.5 hours then poured into 200 ml of diethyl ether. The solid is collected and dried at 50° C. to give 0.125 g of the desired product.

MS(FAB): m/z 529 (M+H) and 627 (M+H2SO4+H).

EXAMPLE 11 [4S-(4α,12aα)]-9-(Acetylamino)-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate (1:2)

To a solution of 0.16 g of product from Example 9 in 0.6 ml of water is added 0.125 g of sodium acetate. After stirring for 5 minutes, 0.05 ml of acetic anhydride is added. The reaction is stirred for 15 minutes, 0.025 ml of ammonium hydroxide is added and the stirring continued for an additional 5 minutes. The mixture is acidified with 0.125 ml of sulfuric acid, extracted with n-butyl alcohol and concentrated in vacuo. The residue is dissolved in methyl alcohol and added to diethyl ether. The solid is collected and dried to give 0.10 g of the desired product.

MS(FAB): m/z 543 (M+H) and 641 (M+H2SO4+H).

EXAMPLE 12 [4S-(4α,12aα)]-7-(Diethylamino)-4-(dimethylamino)-9-(formylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene carboxamide

A solution of 0.2 g of product from Example 10 in 10 ml of water is treated with sodium acetate to achieve pH 5-6. The mixture is extracted with chloroform. The organic extracts are dried with sodium acetate, concentrated in vacuo and the solid triturated with diethyl ether/hexane to give 0.11 g of the desired product.

MS (FAB): m/z 529 (M+H).

EXAMPLE 13 [4S-(4α,12aα)]-9-(Acetylamino)-7-(diethylamino)-4-(dimethylamino)- 1,4,4a,5,5a,6,11 , 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide

A solution of 0.25 g of product from Example 11 in ml of water is treated with sodium acetate to achieve pH 6. The mixture is extracted with chloroform. The organic extracts are dried with sodium acetate, concentrated in vacuo and the solid triturated with diethyl ether/hexane to give 0.090 g of the desired product.

MS (FAB): m/z 543 (M+H).

EXAMPLE 14 [4S-(4α,12aα)]-4-(Dimethylamino)-7-(ethylmethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacene-carboxamide hydrochloride

A solution of 0.460 g of [4S-(4α,12aα)]-4-(dimethylamino)- 7-(ethylamino)-1,4,4a,5,5a,6,11,12 a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Pat. No. 3,226,436, in 0.5 ml of 97% formic acid and 0.75 ml of 40% aqueous formaldehyde is heated at reflux temperature for 2 hours, concentrated to ½ volume and poured into diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.30 g of the desired product.

EXAMPLE 15 [4S-(4α,12aα)]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacene-carboxamide sulfate

The title compound is prepared by the procedure of Example 8, using 0.460 g of product from Example 14, 15 ml of sulfuric acid and 0.101 g of sodium nitrate to give 0.5 g of the desired product.

EXAMPLE 16 [4S-(4α,12aα)]-9-Amino-4-(dimethylamino)-7-(ethylmethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate

The title compound is prepared by the procedure of Example 2, using 1.0 g of product from Example 15, 20 ml of 2-methoxyethanol, 1.0 g of 10% palladium-on-carbon and 5 ml of 2N sulfuric acid to give 0.8 g of the desired product.

EXAMPLE 17 [4S-(4α,12aα)]-4-(Dimethylamino)-7-(ethylmethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

The title compound is prepared by the procedure of Example 3, using 1.5 g of product from Example 16, 0.235 g of anhydrous sodium acetate, 25 ml of 98% formic acid and 3.7 ml of acetic anhydride to give 1.35 g of the desired product.

EXAMPLE 18 [4S-(4α,12aα)]-9-(Acetylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a solution of 3.2 g of [4S-(4α,12aα)]-9-amino- 4-dimethylamino-1, 2,3,4,4a,5,5a,6,11,11a,12,12 a-dodecahydro-10,12aα-dihydroxy-1, 3,11,12-tetraoxo-2-naphthacenecarboxamide, prepared by the procedure described in U.S. Pat. No. 3,239,499, in 50 ml of water is added a solution of 2.5 g of sodium acetate in 12 ml of water. The mixture is cooled to 0° C. and 1 ml of acetic anhydride is added with stirring. The reaction is stirred for 20 minutes, 0.5 ml of ammonium hydroxide is added and stirred for 5 minutes. Two and one half ml of sulfuric acid is added, the reaction is extracted twice with n-butyl alcohol, the combined organic layers are washed with water and concentrated in vacuo. The residue is dissolved in methyl alcohol and added dropwise to 500 ml of diethyl ether. The solid is collected and dried to give 2.3 g of the desired product.

MS(FAB): m/z 472 (M+H) and 570 (M+H2SO4H).

EXAMPLE 19 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide monohydrochloride

To a 0° C. solution of 1.06 g of [4S-(4α,12aα)]-9-amino-4-dimethylamino-1, 2,3,4,5a, 6,11,11a,12,12a-dodecahydro-10,12aα-dihydroxy-1,3,11,12 -tetraoxo-2-naphthacenecarboxamide, prepared by the procedures described in U.S. Pat. No. 3,239,499, in 50 ml of formic acid is added 2.4 ml of acetic anhydride. After stirring for 5 minutes, the cooling bath is removed and the reaction is stirred for 55 minutes. The mixture is added to 400 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 1.1 g of the desired product.

MS(FAB): m/z 458 (M+H).

This procedure is a modification of U.S. Pat. No. 3,239,499.

EXAMPLE 20 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a well stirred 0° C. solution of 0.278 g of product from Example 19 in 10 ml of sulfuric acid is added, in portions, 0.1344 g of N-iodosuccinimide. The reaction is stirred at 0° C. for 20 minutes then poured into 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.251 g of the desired product.

MS (FAB): m/z 584 (M+H).

EXAMPLE [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a well stirred 0° C. solution of 0.278 g of product from Example 19 in 10 ml of sulfuric acid is added 0.3 ml of 10% nitric acid in sulfuric acid. The reaction is stirred at 0° C. for 20 minutes then poured into 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.26 g of the desired product.

MS (FAB): m/z 503 (M+H).

EXAMPLE 22 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-7-(1-methylethyl)amino-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate

A solution of 0.2 g of product from Example 21 (1:2 salt), 0.5 ml of acetone, 0.5 ml of 0.5N sulfuric acid and 10 ml of 2-methoxyethanol is shaken under 35 lbs. of hydrogen, in the presence of platinum oxide, for 2 hours. The catalyst is removed by filtration, the filtrate concentrated in vacuo to ½ volume and poured into diethyl ether. The resulting solid is collected and dried to give 0.135 g of the desired product.

EXAMPLE 23 [4S-(4α,12aα]-(4,7-Bis(dimethylamino)-1,4,4a,5,5a,-6,11,12 a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methoxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide

To a well stirred solution of 0.055 g of product from Example 2, 0.200 g of sodium bicarbonate and 1 ml of N-methylpyrrolidone is added a solution of 0.011 g of methoxyacetyl chloride in 0.5 ml of acetonitrile. After 5 minutes, the suspension is filtered and the filtrate diluted with 50 ml of tert-butyl methyl ether. The resulting solid is collected and dried to give 0.040 g of the desired product.

MS (FAB): m/z 545 (M+H).

EXAMPLE 24 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(cyclopropylcarbonylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g-of sodium bicarbonate, 1.0 ml N-methylpyrrolidone, 0.010 g of cyclopropanecarbonyl chloride and 0.5 ml of acetonitrile to give 0.030 g of the desired product.

EXAMPLE 25 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(chloroacetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1 ml of N-methylpyrrolidone, 0.013 g of chloroacetyl chloride and 0.5 ml of acetonitrile to give 0.035 g of the desired product.

EXAMPLE 26 [4S-(4α,12aα)]-9-[(4-Bromo-1-oxobutyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1 ml of N-methylpyrrolidone, 0.025 g of 4-bromobutyryl chloride and 0.5 ml of acetonitrile to give 0.050 g of the desired product.

MS(FAB): m/z 622 (M+H).

EXAMPLE 27 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(1-oxo-2-propenyl)amino]-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml N-methylpyrrolidone, 0.011 g of acryloyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.

MS(FAB): 513 (M+H).

EXAMPLE 28 [4S-(4α,12aα)]-9-[[(Acetyloxy)acetyl]amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.013 g of acetoxyacetyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.

MS(FAB): m/z 573 (M+H).

EXAMPLE 29 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(phenylthio-acetylamino)-1,4,4a,5,5a,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.110 g of product from Example 2, 0.40 g of sodium bicarbonate, 4.0 ml of N-methylpyrrolidone, 0.035 g of phenylthioacetyl chloride and 0.5 ml of acetonitrile to give 0.075 g of the desired product.

EXAMPLE 30 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(pyruvyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.110 g of product from Example 2, 0.40 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.018 g of pyruvyl chloride and 0.5 ml of acetonitrile to give 0.060 g of the desired product.

EXAMPLE 31 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(ethoxy-carbonylacetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.013 g of ethyl malonyl chloride and 0.5 ml of acetonitrile to give 0.035 g of the desired product.

EXAMPLE 32 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(4-bromo-phenylacetylamino)-1,4,4a,5,5a,6,11,12-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.018 g of 4-bromophenylacetyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.

EXAMPLE 33 [4S-(4α,12aα)]-9-(Benzoylamino)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

To a vigorously stirring solution of 0.066 g of product from Example 2, 0.085 g of sodium acetate and 3 ml of tetrahydrofuran is added 0.015 ml of benzoyl chloride and 0.25 ml of water. The reaction is stirred for 1 hour. The organic layer is decanted, washed with saturated sodium chloride, dried and concentrated in vacuo. The residue is chromatographed on acid-washed diatomaceous earth using a two phase system of hexane-ethyl acetate:2-methoxyethanol:water (50:50:17:6) to give in the second void volume 0.030 g of the desired product as an orange solid.

MS (FAB): m/z 577 (M+H). 1H NMR (d6-DMSO): δ 2.45 (s,6H,C(4)N(CH3)2), 2.57(s,6-H,C(7)N(CH3)2), 7.5-7.6(m, 3H, benzoyl), 7.86(s,1H,H-8), 7.96(d,J=7Hz,2H, benzoyl).

EXAMPLES 34-41

(Table I)

Substantially following the method described in detail hereinabove in Example 33 using [4S-(4α,12aα)]-9-amino-4,7-bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (product from Example 2), the compounds of this invention listed below in Examples 34-41 are prepared.

TABLE I Ex. Acid Chloride Product Spectra 34 4-Methoxybenzoyl [4S-(alpha,12aalpha))]-4,7- MS(FAB): m/z 607(M+H); 1H NMR chloride Bis(dimethylamino)-1,4,4a,5 (d6-DMSO): delta 2.45(s, 6H, 5a,6,11,12a-octahydro-3,10, C(4)NMe2), 2.57(s, 6H, C(7) 12,12a-tetrahydroxy-9-[(4- NME2), 7.06(d, J=9Hz, 2H of 4- methoxybenzoyl)amino]-1,11- methoxybenzoyl), 7.84(s, 1H, dioxo-2-naphthacenecarbox- H-8), 7.97(d, J=9Hz, 2H of 4- amide methoxybenzoyl) 35 2-Methylbenzoyl [4S-(4alpha,12aalpha))]-4,7- MS(FAB): m/z 591(M+H); 1H NMR chloride Bid(dimethylamino)-1,4,4a,5 (d6-DMSO): delta 2.52(m, 12H, 5a,6,11,12a-octahydro-3,10, C(4)NMe2, & C(7)NMe2), 7.25- 12,12a-tetrahydroxy090[(2- 7.56(m, 4H from 2-methyl- methylbenzoyl)amino]-1,11- benzoyl), 7.98(s, 1H, H-8) dioxo-2-naphthacenecarbox- amide 36 2-Fluorobenzoyl [4S-(4alpha,12aalpha))]-4,7- MS(FAB): m/z 595(M+H): 1H NMR chloride Bis(dimethylamino)-9-[(2- (d6-DMSO): delta 2.47-2.51 fluorobenzoyl)amino]-1,4,4a, (m, 6H, C(4)NMe2), 2.57(bs, 6H, 5,5a,6,11,12a-octahydro-3,10, C(7)NMe2), 7.39(m, 2H from 12,12a-tetrahydroxy-1,11- 2-fluorobenzoyl), 7.63(m, 1H dioxo-2-naphthacenecarbox- from 2-fluorobenzoyl), (m, amide 1H from 2-fluorobenzoyl), 8.24(s, 1H, H-8) 37 Pentafluoro- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 667(M+H); 1H NMR benzoyl chloride Bis(dimethylamino)-1,4,4a, (d6-DMSO): delta 2.5(m, 12H, 5,5a,6,11,12a-octahydro-3,10, C(4)NMe2 & C(7)NMe2), 8.08 12,12a-tetrahydroxy-9- (s, 1H, H-8) [(pentafluorobenzoyl)amino]- 1,11-dioxo-2-naphthacenecar- boxamide 38 3-Trifluoro- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 645(M+H); 1H NMR methylbenzoyl Bis(dimethylamino)-1,4,4a,5, (d6-DMSO): delta 250(m, 6H, chloride 5a,6,11,12a-octahydro-3,10, C(4)NMe2), 2.57(m, 6H, C(7) 12,12a-tetrahydroxy-1,11- NMe2), 7.85(m, 2H of 3-tri- dixox-9-[[3-(trifluoro- fluoromethylbenzoly), 7.99 methyl)benzoyl]amino]-2- (m, 1H or 3-trifluoromethyl- naphthacenecarboxamide benzoyl), 8.28(1H of 3-tri- fluoromethylbenzoyl), 8.33 (s, 1H, H-8), 8.31-8.42(m, 2H) 39 2-Furoyl [4S-(alpha,12aalpha)]-4,7- MS(FAB): m/z 567(M+H); 1H NMR chloride Bis(dimethylamino)-9-[(2- (d6-DMSO): delta 2.47(m, 6H, furanylcarbonyl)amino]-1,4, C(4)NMe2), 2.56(s, 6H, C(7) 4a,5,5a,6,11,12a-octahydro- NMe2), 6.73(s, 1H of furanyl) 3,10,12,12a-tetrahydroxy- 7.31(s, 1H of furanyl), 7.95 1,11-dioxo-2-naphthacene- (s, 1H of furanyl(, 8.00(s, carboxamide 1H, H-8) 40 2-Thiophene- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 583(M+H); 1H NMR carbonyl Bis(dimethylamino)-1,4,4a, (d6-DMSO): delta 2.49(m, 6H, chloride 5,5a,6,11,12a-octahydro- C(4)NMe2), 2.56(s, 6H, C(7) 3,10,12,12a-tetrahydroxy- NMe2), 7.21(m, 1H of 1,11-dioxo-9-[(2-thienyl- thienyl), 7.70(s, 1H, H-8), carbonyl)amino]-2-naphtha- 7.85(m, 1H of thienyl), 8.01 cenecarboxamide (m, 1H of thienyl) 41 4-Nitro- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 622(M+H); 1H NMR benzoyl Bis(dimethylamino)-1,4,4a, (d6-DMSO): delta 2.50(m, 6H, chloride 5,5a,6,11,12a-octahydro- C(4)NMe2), 2.57(s, 6H, C(7) 3,10,12,12a-tetrahydroxy-9- NMe2), 7.76(s, 1H, H-8), 8.20 [(4-nitrobenzoyl)amino]- (d, J=9Hz, 2H of 4-nitro- 1,11-dixox-2-naphthacene- nitrobenzoyl), 8.36(d, J=9Hz, 2H of carboxamide 4-nitrobenzoyl)

EXAMPLE 42 [4S-(4α,12aα)]-9-[(4-Aminobenzoyl)amino]-4,7-Bis-dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate

A mixture of 0.030 g of product from Example 41, 0.010 g of 10% palladium-carbon, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid, in a pressure bottle, is shaken under 30 lbs. of hydrogen pressure for 40 minutes. The catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with benzene. The oily residue is dissolved in 0.5 ml of 2-methoxyethanol, precipitated with diethyl ether and the solid collected to give 0.018 g of the desired product.

MS(FAB): m/z 592 (M+H).

EXAMPLE 43 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[[(4-dimethylamino)benzoyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide

A mixture of 0.065 g of product from Example 41, 2.0 ml of 2-methoxyethanol, 0.025 g of 10% palladium-on-carbon, 0.4 ml of 2N sulfuric acid and 0.3 ml of 37% aqueous formaldehyde, in a pressure bottle, is shaken under 30 lbs. of hydrogen pressure for 50 minutes. The catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with heptane. The oily residue is dissolved in 1.0 ml of 2-methoxyethanol, precipitated with diethyl ether to give 0.085 g of the desired product as the sulfate salt. The sulfate salt is dissolved in 0.5 ml of water and 6 ml of tetrahydrofuran followed by the addition of 0.10 g of sodium acetate. The organic layer is washed with saturated sodium chloride, dried and concentrated in vacuo. The residue is triturated with ethyl acetate/heptane to give 0.035 g of the desired product as the free base.

MS (FAB): m/z 620 (M+H).

1H NMR (d6-DMSO): δ 2.50(m,6H,C(4)NMe2), 2.57(s, 6H, C(7) NMe2), 3.33 (s,6H, NMe2 of 4-dimethylaminobenzoyl), 7.76(s,1H,H-8), 8.20(d,J=9Hz,2H of 4-dimethylaminobenzoyl), 8.37(d,J=9Hz,2H of 4-dimethylaminobenzoyl).

EXAMPLE 44 [7S-(7α,10aα)]-[2-[[9-(Aminocarbonyl)-4,7-Bis-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-β-naphthacenyl]-amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester

A mixture of 0.850 g of product from Example 2 (as the disulfate), 0.680 g of sodium acetate in 25 ml of tetrahydrofuran and 5 ml of water is stirred at 25° C. for 5 minutes. The solution is treated with 0.359 g of (succinimyloxycarbonyl)methyl carbamic acid tert-butyl ester, stirred for 2 hours and extracted with chloroform. The organic layer is concentrated in vacuo to give 0.50 g of the desired product.

MS(FAB): m/z 630 (M+H).

EXAMPLE 45 [4S-(4α,12aα)]-9-[(Aminoacetyl)amino]-4,7-Bis-dimethylamino)-1,4,4a,5.,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono(trifluoroacetate).

A solution of 0.030 g of product from Example 44 and 1.0 ml of trifluoroacetic acid is maintained at 24° C. for 24 hours followed by concentrating in vacuo. The residue is triturated with methyl alcohol and the solid collected to give 0.024 g of the desired product.

MS (FAB): m/z 530 (M+H).

EXAMPLE 46 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate

A mixture of 0.030 g of product from Example 45, 0.020 g of 10% palladium-on-carbon, 0.5 ml of 37% formaldehyde, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid, in a pressure bottle, is shaken under 30 lbs. of hydrogen pressure for 40 minutes. The catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with benzene. The oily residue is dissolved in 0.5 ml of 2-methoxyethanol, precipitated with diethyl ether and the precipitate collected to give 0.025 g of the desired product.

EXAMPLE 47 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(phenylsulfonyl)amino]-2-naphthacenecarboxamide

A mixture of 0.30 g of product from Example 2, 0.40 g of sodium acetate in 10 ml of tetrahydrofuran and 1.5 ml of water is stirred for 10 minutes under argon. The organic layer is separated, dried over anhydrous sodium sulfate and treated with 0.125 ml of benzenesulfonyl chloride and 0.60 g of sodium bicarbonate. The reaction is stirred vigorously for 1.5 hours. The organic layer is decanted and codistilled with heptane. The residue is dissolved in ethyl acetate, dried and concentrated in vacuo. The residue is chromatographed on diatomaceous earth using hexane:ethyl acetate:2-methoxyethanol:water (35:65:15:5) to give 0.036 g of the desired product as a yellow solid.

MS(FAB): m/z 613 (M+H).

1H NMR (CDCl3): δ 2.44(bs,6H,C(4)NMe2), 2.55(s,6H, C(7)NMe2, 7.38-7.45(m,2H,m-H's from benzenesulfonyl), 7.52-7.56(m, 1H,p-H from benzenesulfonyl), 7.58(s,1H,H-8), 7.78(dj=7Hz,2H,o-H's from benzenesulfonyl).

EXAMPLES 48-53

(Table II)

Substantially following the method described in detail hereinabove in Example 47 using [4S-(4α,12aα)]-9-amino-4,7-bis(dimethylamino)-1,4,4a, 5,5a,6,11,12 a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (product from Example 2) and the appropriate alkyl, aryl or heteroarylsulfonyl chloride, the compounds of this invention listed below in Examples 48-53 are prepared.

TABLE II Ex. Sulfonyl Chloride Product Spectra 48 4-Chlorobenzene- [4S-(4alpha,12aalpha))]-9- MS(FAB): m/z 622(M+H); 1H NMR sulfonyl chloride [[4-chlorophenyl)sulfonyl]- (d6-DMSO): delta 2.48(m, 12H, amino]-4,7-bis(dimethyl- C(4)NMe2 & C(7)NMe2), 7.16 amino)-1,4,4a,5,5a,6,11,12a- (s, 1H, H-8), 7.62(d, J=9Hz, 2H tetrahydroxy-1,11-dioxo-2- of 4-chlorobenzenesulfonyl), naphthacenecarboxamide 7.75(d, J=9Hz, 2H of 4-chloro- benzenesulfonyl) 49 3-Nitrobenzene- [4S-(4alpha,12aalpha))]-4,7- MS(FAB): m/z 658(M+H); 1H NMR sulfonyl chloride Bis(dimethylamino)-1,4,4a,5 (d6-DMSO): delta 2.44-2.45 5a,6,11,12a-octahydro-3,10, (m, 12H, C(4)NMe2) & C(7)NMe2) 12,12a-tetrahydroxy-9-[(3- 7.51-7.62(m, 3H of 3-nitro- nitrophenyl)sulfonyl]amino]- benzenesulfonyl), 7.74-7.78 1,11-dioxo-2-naphthacenecar- (m, 1H or 3-nitrobenzenesul- boxamide fonyl), 7.75(s, 1H, H-8) 50 4-Nitrobenzene- [4S-(4alpha,12aalpha))]-4,7- MS(FAB): m/z 658(M+H); 1H NMR sulfonyl chloride Bis(dimethylamino)-1,4,4a,5, (CDCl3): delta 2.46(s, 6H, C(4) 5a,6,11,12a-octahydro-3,10, NMe2), 2.58(s, 6H, C(7)NMe2), 12,12a-tetrahydroxy-9- 7.59(s, 1H, H-8), 7.96(d, J= [[(4-nitrophenyl)sulfonyl] 9Hz, 2H of 4-nitrobenzene- amino]-1,11-dioxo-2- sulfonyl), 8.25(d, J=9Hz, naphthacenecarboxamide 2H of 4-nitrobenzene- sulfonyl). 51 2-Thiophene [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 619(M+H); 1H NMR sulfonyl Bis(dimethylamino)-1,4,4a,5, (d6-DMSO): delta, 2.50(m, 6H, chloride 5a,6,11,12a-octahydro-3,10, C(4)NMe2), 2.54(s, 6H, C(7) 12,12a-tetrahydroxy-1,11- NMe2), 7.14(m, 1H or thienyl), dioxo-9-[(2-thienylsulfonyl) 7.20(m, 1H or thienyl), 7.51 amino]-2-naphthacenecarbox- (s, 1H of thienyl), 7.91(s, amide 1H, H-8) 52 2-Acetamido-4- [4S-(4alpha,12aalpha)]-9- MS(FAB): m/z 691(M+H); 1H NMR methyl-5-thiazole [[(2-(Acetylamino)-4-methyl- (CDCl3) delta 2.21(s, 3H thia- sulfonyl 5-thiazoyl]sulfonyl]amino]- zoyl H3CCONH), 2.40(s, 3H, chloride 4,7-bis(dimethylamino)-1,4, thiazoyl H3C), 2.54(s, 6H, C(4) 4a,5,5a,6,11,12a-octahydro- NMe2), 2.57(s, 6H, C(7)NMe2), 3,10,12,12a-tetrahydroxy-1, 7.65(s, 6H, C(7)NMe2, 7.65(s, 11-dioxo-2-naphthacenecar- 1H, H-8) boxamide 53 Ethane sulfonyl [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 565(M+H); 1H NMR chloride Bis(dimethylamino)-9- (CDCl3): delta 0.88(t, 3H, CH3 [(ethylsulfonyl)amino]-1,4, CH2SO2), 2,4-2.6(m, 12H, C(4) 4a,5,5a,6,11,12a-octahydro- NMe2 & C(7)NMe2), 3.34(q, 2H, 3,10,12,12a-tetracydroxy- CH3CH2SO2), 7.61(s, 1H, H-8) 1,11-dioxo-2-naphthacene- carboxamide

EXAMPLE 54 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide

A solution of 0.30 g of product from Example 3 and 1.2 equivalents of 30% aqueous formaldehyde in 6.0 ml of 2-methoxyethanol is treated with 5.0 equivalents of pyrrolidine. The reaction is stirred vigorously at room temperature for 1.5 hours. The crystalline solid is collected and dried to give 0.25 g of the desired product.

MS (FAB): m/z 584 (M+H).

EXAMPLE 55 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methanesulfonyl)amino]-1,11-dioxo-2-naphthacene-carboxamide

A mixture of 0.30 g of product from Example 2, 0.40 g of sodium acetate in 10 ml of tetrahydrofuran and 1.5 ml of water is stirred for 10 minutes at room temperature under argon. The organic layer is separated, dried over sodium sulfate, filtered and treated with 0.10 ml of methanesulfonyl chloride and 0.60 g of sodium bicarbonate. The reaction is stirred vigorously for 1.5 hours. The organic layer is decanted and codistilled with heptane. The residue is dissolved in ethyl acetate, dried and concentrated in vacuo. The crude product is chromatographed on diatomaceous earth using hexane:ethyl acetate:2-methoxyethanol:water (35:65:15:5) to give 0.016 g of the desired product as a yellow solid.

MS (FAB): m/z 551 (M+H).

EXAMPLE 56 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[(methanesulfonyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(pyrrolidinylmethyl)-2-naphthacenecarboxamide

A solution of 0.30 g of product from Example 55 and 1.2 equivalents of 30% aqueous formaldehyde in 6.0 ml of 2-methoxyethanol is treated with 5.0 equivalents of pyrrolidine. The reaction is stirred vigorously at room temperature for 1.5 hours. The crystalline solid is collected and dried to give 0.250 g of the desired product.

MS (FAB): m/z 634 (M+H).

EXAMPLE 57 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(phenylmethoxy)acetyl]amino]-2-naphthacenecarboxamide

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidine, 0.018 g of benzyloxyacetyl chloride and 0.5 ml of acetonitrile to give 0.060 g of the desired product.

MS(FAB): m/z 622 (M+H).

EXAMPLE 58 [7S-(7α,10aα)]-[[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]oxoacetic acid ethyl ester

The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.015 g of ethyl oxalyl chloride and 0.5 ml of acetonitrile to give 0.030 g of the desired product.

MS (FAB): m/z 574 (M+H).

EXAMPLE 59 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(hydroxyacetyl)amino]-1,11-dioxo-2-naphthacene-carboxamide

A mixture of 0.048 g of product from Example 28 and 0.6 ml of concentrated sulfuric acid is stirred at room temperature for 2 hours, poured into diethyl ether and the precipitated salt collected. The salt is dissolved in 10 ml of tetrahydrofuran, 0.250 g of sodium acetate is added and the mixture stirred for 1 hour. The reaction is filtered and the filtrate is concentrated in vacuo. The residue is chromatographed on a poly(styrene-vinyl benzene)copolymer column with water:acetonitrile (1:1) to give 0.018 g of the desired product as a light yellow solid.

MS (FAB): m/z 532 (M+H).

EXAMPLE 60 [4S-(4α,12aα)]-9-(Acetylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a 0° C. solution of 1.06 g of [4S-(4α,12aα)]-9-amino-4-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,11a,12,12a-dodecahydro-10,12aα-dihydroxy-1,3,11,12-tetraoxo-2-naphthacenecarboxamide, prepared by the procedures described in U.S. Pat. No. 3,239,499, in 50 ml of acetic acid is added 2.4 ml of acetic anhydride. After 5 minutes, the reaction is allowed to warn to room temperature. The reaction mixture is poured into 500 ml of diethyl ether and the resulting precipitate is collected. The precipitate is washed with diethyl ether and dried to give 1.1 g of the desired product.

MS(FAB): m/z 472 (M+H).

EXAMPLE 61 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(acetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide sulfate

To a stirring 0° C. solutin of 0.278 g of product from Example 60 in 10 ml of sulfuric acid is added, portionwise, 0.1344 g of N-iodosuccinimide. After stirring at 0° C. for 20 minutes, the reaction mixture is poured into 400 ml of diethyl ether. The resultant precipitate is collected, washed with diethyl ether and dried to give 1.1 g of the desired product as a solid.

MS(FAB): m/z 598 (M+H) and 696 (M+H2SO4+H).

EXAMPLE 62 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid methyl ester

To a room temperature mixture of 0.60 g of product from Example 2 in 2 ml of 1-methyl-2-pyrrolidinone is added 0.60 g of sodium bicarbonate. The mixture is stirred for 5 minutes followed by the addition of 0.12 ml of methyl chloroformate. The reaction is stirred at room temperature for 30 minutes and filtered into 200 ml of t-butyl methyl ether. The resulting solid is collected and dried to give 0.370 g of the desired product.

MS (FAB): m/z 531 (M+H).

1H NMR (d6DMSO): δ 2.6(s,12H,C(4)NMe2 and C(7)NMe2), 3.7(m,3H,o-CH3), 7.8(s,1H,H-3), 8.7(s,1H,aromatic NH), 9.1 (d,2H, CONH2).

EXAMPLE 63 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid (2-diethylamino)ethyl ester

The title compound is prepared by the procedure of Example 62, using 0.443 g of product from Example 2, 2 ml of 1-methyl-2-pyrrolidone, 0.165 g of β-diethylaminoethyl chlorocarbonate hydrochloride and 0.443 g of sodium bicarbonate to give 0.350 g of the desired product.

1H NMR (d6DMSO): δ 1.2(m,6H,—N(CH2CH3)2), 2.5(s,6H, C(7)NMe2), 2.7(s,6H,C(4)NMe2), 3.4(m,2H, OCH2CH2N), 3.51(m,4H,—N(CH2CH3)2), 4.0(m,2H,—OC H2CH2N), 6.8(s,1H,H-3), 9.0(d,2H,CONH2).

EXAMPLE 64 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid ethenyl ester

The title compound is prepared by the procedure of Example 62, using 0.189 g of product from Example 2, 1 ml of 1-methyl-2-pyrrolidone, 0.75 ml of acetonitrile, 0.20 g of sodium bicarbonate and 0.037 g of vinyl chloroformate to give 0.133 g of the desired product.

MS (FAB): m/z 548 (M+H).

1H NMR (d6DMSO+TFA): δ 4.35(s,1H,H-7), 4.6(d,1H, CH═CH2cis), 4.9(d,1H,CH═CH2,trans), 7.2(m,2H, —O—CH═CH2), 8.1(s,1H,H-3), 9.6 & 9.1(s,2H,CONH2), 9.61(s,H,aromatic NH)

EXAMPLE 65 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid 2-propenyl ester

The title compound is prepared by the procedure of Example 62, using 0.213 g of product from Example 2, 1 ml of 1-methyl-2-pyrrolidone, 0.75 ml of acetonitrile, 0.20 g of sodium bicarbonate and 0.054 g of allyl chloroformate to give 0.143 g of the desired product.

1H NMR (d6DMSO+TFA): δ 4.65(d,2H,═CHCH2), 5.25(d,1H,CH═CH2cis), 5.4(d,1H,CH═CH2trans), 6.0(m, 1H,CH2═CH—CH2), 8.1(s,1H,H-3), 9.1(s,1H,aromatic NH), 9.6 & 9.0(s,2H,CONH2).

Substantially following the methods described in detail hereinabove in Example 23, the compounds of this invention listed below in Examples 66-82 are prepared. Example 72 uses the appropriate anhydride rather than the acid chloride.

EXAMPLE 66 [4S-(4α,12aα)]-4-(Dimethylamino)-9-[[(4-fluorophenoxy)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12 a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 67 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-2-thiopheneacetamide. EXAMPLE 68 [4S-(4α,12aα)]-9-[[(Diethylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 69 [4S-(4α,12aα)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-9-[[(methylthio)acetyl]amino]-1,11-dioxo-2-naphthacene-carboxamide. EXAMPLE 70 [4S-(4α,12aα)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(1-methyl-ethyl)amino]-1,11-dioxo-9-[(3,3,3-trichloro-1-oxopropyl)amino]-2-naphthacenecarboxamide. EXAMPLE 71 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[(1,3-dioxo-3-Phenylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,12-dioxo-2-naphthacenecarboxamide. EXAMPLE 72 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[4-(dimethylamino)-1-oxobutyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide. EXAMPLE 73 [4S-(4α,12aα)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(phenylsulfonyl)acetyl]amino]-2-naphthacene-carboxamide. EXAMPLE 74 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a-octahydro-1,8,10a,11-tetrahydroxy-4-iodo-10,12-dioxo-2-naphthacenyl]-5-methyl-2-furanacetamide. EXAMPLE 75 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12 -dioxo-2-naphthacenyl]-2-thiazoleacetamide. EXAMPLE 76 [7S-(7α,10aα)]-2-[[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-carbonyl]benzoic acid. EXAMPLE 77 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-3-methyl-2-oxo-1-imidazolidineacetamide. EXAMPLE 78 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-5,6-dimethylpyrazinecarboxamdie. EXAMPLE 79 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-3-methyl-3H-imidazo[4,5-b]pyridine-2-acetamide. EXAMPLE 80 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(pentafluorophenyl)acetyl]amino]-2-naphthacenecarboxamide. EXAMPLE 81 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-4-iodo-10,12-dioxo-2-naphthacenyl]-4-ethyl-2,3-dioxo-1-piperazinecarboxamide. EXAMPLE 82 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-4-ethyl-2,3-dioxo-1-piperazinecarboxamide. EXAMPLES 83-86

Substantially following the methods described in detail hereinabove in Example 44, the compounds of this invention listed below in Examples 83-86 are prepared.

EXAMPLE 83 [7S-(7α,10aα)]-[2-[[9-Aminocarbonyl-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-1,12 10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester. EXAMPLE 84 [7S-[2(S*),(7α,10aα)]]-[2-[[9-(Aminocarbonyl)-4-(diethylamino)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-1-methyl-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester. EXAMPLE 85 [7S-[2(S*),(7α,10aα)]]-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-2-oxo-1-phenylethyl]carbamic acid 1,1-dimethylethyl ester. EXAMPLE 86 [7S-[2(S*),(7α,10aα)]]-[4-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxobutanoic acid 1,1-dimethylethyl ester. EXAMPLES 87-91

Substantially following the methods described in detail hereinabove in Example 45, the compounds of this invention listed below in Examples 87-91 are prepared.

EXAMPLE 87 [4S-(4α,12aα)]-9-[(Aminoacetyl)amino]-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 88 [4S-(4α,9(S*),12aα)]-9-[(2-Amino-1-oxopropyl)-amino]-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 89 [4S-(4α,9(S*),12aα)]-9-[(Aminophenylacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacence-carboxamide. EXAMPLE 90 [7S-[2(S*),7α,10aα)]]-3-Amino-4-[[9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-4-oxobutanoic acid. EXAMPLE 91 [7S-[2(S*),7α,10aα)]]-4-[[9-(Aminocarbonyl)-4,7-bis-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10,10a-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-3-(dimethylamino)-4-oxobutanoic acid. EXAMPLES 92-94

Substantially following the methods described in detail hereinabove in Example 47, the compounds of this invention listed below in Examples 92-94 are prepared.

EXAMPLE 92 [4S-(4α,12aα)]-4-(Dimethylamino)-9-[[(2,2-dimethylpropyl)sulfonyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(1-methylethyl)amino]-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 93 [7S-(7α,10aα)]-4-[[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-sulfonyl]butanoic acid. EXAMPLE 94 [4S-(4α,12aα)]-4-(Dimethylamino)-9-[[(1,1-dimethylethyl)sulfonyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 95 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[[(diethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate

The title compound is prepared by the procedure of Example 46, using 0.030 g of product from Example 45, 0.020 g of 10% palladium-on-carbon, 2.5 equivalents of acetaldehyde, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid to give the desired product as a solid.

EXAMPLE 96

Dimethylaminoacetyl chloride hydrochloride

A mixture of 15 g of N,N-dimethylglycine hydrochloride (pulverized and dried in a vacuum oven at 45°-50° C. for 24 hours) and 13.85 ml of thionyl chloride is heated, very slowly, in a sand bath to 78° C. and kept at this temperature for 1½ hours. Toluene is added to the mixture and the excess liquid is removed by pipette. This step is repeated several times. The solid is then transferred to a Buchner funnel, washed with methylene chloride and dried under vacuum at 50° C. for 24 hours to yield 14.2 g of the desired intermediate.

EXAMPLE 97 [4S-(4alpha,12alpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

To a mixture of 6.68 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline in 120 ml of DMPU and acetonitrile is added 6.57 g of sodium carbonate. The mixture is stirred for 5 minutes, followed by the addition of 2.83 g of product from Example 96. The reaction is stirred for 1 hour, filtered and the filtrate is added slowly to a mixture of methylene chloride/diethyl ether (1200 ml/400 ml). The solid is collected, dissolved in 250 ml methyl alcohol and added slowly to 1600 ml of methylene chloride. The precipitate is collected, washed with diethyl ether and dried to give 5.75 g of the desired product.

MS(FAB): m/z 558 (M+H).

EXAMPLE 98 [4S-(4alpha,12alpha)]-9-[(Chloroacetyl)amino]-4,7-bis-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,1-dioxo-2-naphthacene-carboxamide dihydrochloride

To a room temperature solution of 0.334 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline sulfate, 6 ml of 1,3-dimethyl-3,4,5,6-tetrahydro- 2(1H)pyrimidinone, hereinafter called DMPU, and 2 ml of acetonitrile is added 0.318 g of sodium carbonate. The mixture is stirred for 5 minutes followed by the addition of 0.068 g of chloroacetyl chloride. The reaction is stirred for 30 minutes, filtered, and the filtrate added dropwise to 100 ml of diethyl ether, containing 1 ml of 1M hydrochloric acid in diethyl ether. The resulting solid is collected and dried to give 0.340 g of the desired product.

MS(FAB): m/z 549 (M+H).

EXAMPLE 99 [4S-(4alpha,12alpha)]-9-[(Bromoacetyl)amino]-4,7-bis-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide dihydrochloride

The title compound is prepared by the procedure of Example 98, using 0.668 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline sulfate, 6 ml of DMPU, 2 ml of acetonitrile, 0.636 g of sodium carbonate and 0.215 g of bromoacetyl chloride. Seven tenths of a gram of the desired product is obtained.

MS (FAB): m/z 593 (M+H).

EXAMPLE 100 [4S-(4alpha,12alpha)]-9-[(Bromoacetyl)amino]-4,7-bis-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide (free base)

To 0.20 g of product from Example 99 in 3 ml of 1,3-dimethyl-2-imidazolidenone is added 0.30 g of sodium bicarbonate. The reaction is stirred at room temperature for 15 minutes and filtered. The filtrate is added to 15 ml of diethyl ether and the resulting precipitate is collected to give 0.150 g of the desired product as the free base.

EXAMPLE 101 [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis-(dimethylamino)-1,4,4a,5,5a,6,10,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide monohydrobromide

To a solution of 5.01 g of 9-amino-4,7-bis-(dimethylamino)- 6 -demethyl-6-deoxytetracycline, 100 ml of DMPU and 25 ml of acetonitrile is added 5.0 g of sodium carbonate. The reaction is stirred, under argon, at room temperature for 5 minutes, followed by the addition of 3.03 g of bromoacetyl bromide. The stirring is continued for an additional hour. The solid is collected and the filtrate is added slowly to isopropyl alcohol/diethyl ether (200 ml/750 ml). The yellow solid is collected, washed with isopropanol and diethyl ether to give 5.77 g of the desired intermediate.

MS (FAB) :m/z 593 (M+H).

EXAMPLE 102 [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)-amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrobromide

The title compound is prepared by the procedure of Example 98, using 1.00 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline, 1.0 g of sodium carbonate and 0.648 g of 2-bromopropionyl bromide to give 0.981 g of the desired product.

MS(FAB): m/z 607 (M+H).

EXAMPLE 103 [4S-(4alpha,12aalpha)]-9-[(4-Bromo-1-oxobutyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

The title compound is prepared by the procedure of Example 98, using 1.34 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline sulfate, 1.3 g of sodium carbonate, 24 ml of DMPU, 8 ml of acetonitrile and 0.389 g of 4-bromobutyryl chloride to give 1.45 g of the desired product.

EXAMPLE 104 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride

To a solution of 0.15 g of product from Example 99 in 4 ml of DMPU is added 0.85 g of dimethylamine (40% in water). The reaction is stirred for 20 minutes followed by concentration in vacuo to remove any excess dimethylamine. The mixture is filtered and the filtrate added, dropwise, to 70 ml of isopropyl alcohol/diethyl ether (1:1). To this solution is added 1 ml of 1M hydrochloric acid/diethyl ether. The resulting precipitate is collected, washed with isopropyl alcohol and diethyl ether, and dried to give 0.11 g of the desired product.

MS (FAB): m/z 558 (M+H).

EXAMPLE 105 [4S-(4alpha,12aalpha]]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[(methylamino)acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride (331,256)

A mixture of 0.1258 g of product from Example 99, 5 ml of 40% methylamine in water and 5 ml of methyl alcohol, under Argon, is stirred at room temperature for 30 minutes. The excess methylamine is removed in vacuo and the residue diluted with a small volume of methyl alcohol. The diluted reaction solution is added dropwise to 100 ml of diethyl ether containing 1 ml of 1M hydrochloric acid in diethyl ether and 10 ml of isopropyl alcohol. The resulting solid is collected and dried to give 0.106 g of the desired product.

MS (FAB): m/z 544 (M+H).

Substantially following the methods described in detail herein above in Example 105, the compounds of this invention listed below in Examples 106-125 are prepared.

Starting Example Material Rx MS(FAB): # Name Prod. of Exp. Reactant Time m/z 106 [7S-(7alpha,10aalpha)[-N-[(Aminocarbonyl)-4,7-bis(di- 99 Morpholine 0.5 hr. 600(M+H) methylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11- tetrahydroxy-10,12-dioxo-2-naphthacenyl]-4-morpholineacet- amide dihydrochloride. 107 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(ethyl- 99 Ethylamine   2 hr. 558(M+H) amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,- (70% in water) 12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 108 [4S-(4alpha,12aalpha)]-9-[[(Cyclopropylamino)acetyl]amino]- 99 Cyclopropylamine   2 hr. 570(M+H) 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,- 12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide di- hydrochloride. 109 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(butyl- 99 Butylamine   2 hr. 586(M+H) amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,- 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihy- drochloride. 110 [4S-(4alpha,12aalpha)]-9-[[(Diethylamino)acetyl]amino]-4,7- 99 Diethylamine   2 hr. 586(M+H) bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,12,12,- 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihy- drochloride. 111 [7S-(7alpha,10aalpha)-N-[9-(Aminocarbonyl)-4,7-bis(dimethyl 99 Pyrrolidine 0.5 hr. 584(M+H) amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahy- droxy-10,12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide dihydrochloride. 112 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Isobutylamine   2 hr. 586(M+H) 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[[(2-methyl- propyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarbox- amide dihydrochloride. 113 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(di- 99 Piperdine   1 hr. 598(M+H) methylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11- tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-piperidineacet- amide dihydrochloride. 114 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(di- 99 Imidazole   1 hr. 579(M+H) methylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11- tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1H-imidazole-1- acetamide dihydrochloride. 115 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Propylamine 0.75 hr.  570(M+H) 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [[(propylamino)acetyl]amino]-2-naphthacenecarboxamide dihydrochloride. 116 [4S-(4alpha,12aalpha)]-4,7-Bis)dimethylamino)-9-[[dimethyl- 99 Dimethylamine 0.5 hr. 558(M+H) amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide disulfate. 117 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[dimethyl- 99 Dimethylamine 0.5 hr. 558(M+H) amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. 118 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-9-[[(hexyl- 99 n-Hexylamine   2 hr. 614(M+H) amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,- 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 119 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-9-[[(dimethyl- 102 Dimethylamine 2.5 hr. 572(M+H) amino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3, (40% in water) 10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 120 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11, 102 Methylamine   2 hr. 558(M+H) 12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[2-methylamino)-1- (40% in water) oxopropyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 121 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethyl- 102 Pyrrolidine   1 hr. 598(M+H) amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetra- droxy-10,12-dioxo-2-naphthacenyl]-alpha-methyl-1-pyrrolidine- acetamide dihydrochloride. 122 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-9-[[4-dimethyl- 103 Dimethylamine   2 hr. 586(M+H) amino)-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10, (40% in water) 12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride. 123 [4S-(4alpha,12aalpha)]-9-[[(Butylmethylamino)acetyl]amino]- 99 N-Methylbutyl-   2 hr. 600(M+H) 4,7-bis(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, amine 12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride 124 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Amylamine   2 hr. 600(M+H) 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [[[(pentylamino)acetyl]amino]-2-naphthacenecarboxamide dihydrochloride. 125 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Benzylamine   1 hr. 620(M+H) 6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9- [[[phenylmethyl)amino]acetyl]amino]-2- naphthacenecarboxamide dihydrochloride.

EXAMPLE 126 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)5,5a,6,6a,7,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-2-oxoethyl]glycine phenylmethyl ester

To 0.30 g of benzylglycine hydrochloride in 3 ml of 1,3-dimethyl-2-imidazolidinone is added 0.60 g of sodium bicarbonate. The mixture is stirred at room temperature for 15 minutes and filtered. To the filtrate is added 0.20 g of product from Example 100. The reaction mixture is stirred at room temperature for 1 hour and then added to diethyl ether. The resulting solid is collected.

EXAMPLE 127 [7S-(7alpha,10aalpha]]-N-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-2-oxoethyl]glycine

One-tenth of a gram of product from Example 126 in 10 ml of monomethyl ethylene glycol is reduced catalytically, in a Parr shaker, with 0.10 g of 10% palladium on carbon, at 30 psi of hydrogen, for 2 hours. The reaction mixture is filtered and the filtrate concentrated to give 0.050 g of the desired product.

CI-MS: m/z 588 (M+H).

General Procedure for the Preparation of Mannich Bases

A mixture of 0.5 g of product from Example 117, 3 ml of t-butyl alcohol, 0.55 ml of 37% formaldehyde, and 0.55 ml of pyrrolidine, morpholine or piperidine is stirred at room temperature for 30 minutes followed by heating at 100° C. for 15 minutes. The reaction mixture is cooled to room temperature and triturated with diethyl ether and hexane. The solid is collected, washed with diethyl ether and hexane, and dried to give the desired product.

In this manner the following compounds are made:

EXAMPLE 128 [4S-(4alpha12aalpha]]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,122a-tetrahydroxy-1,11-dioxo-N-(1-pyrrolidinyl-methyl)-2-naphthacenecarboxamide EXAMPLE 129 [4S-(4alpha,12aalpha]]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(4-morpholinyl-methyl)-2-naphthacenecarboxamide EXAMPLE 130 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-piperidinylmethyl)-2-naphthacenecarboxamide EXAMPLE 131 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-napthacenyl]-1-azetidineacetamide

The title compound is prepared by the procedure of Example 105 using 0.20 g of product form Example 99, 0.50 g of azetidine and 5 ml of DMPU to give 0.126 g of the desired product.

MS(FAB): m/z 570(M+H).

EXAMPLE 132 [4S-(4alpha,12aalpha)]-9-[[(Cyclobutylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride

To a solution of 0.200 g of 9-(bromoacetylamino)-7-dimethylamino-6-demethyl-6-deoxytetracycline in 2 ml of 1,3-demethyl-2-imidazolidinone is added 0.1 ml of cyclobutylamine. The resulting solution is stirred at room temperature for 45 minutes and then added to 50 ml of diethyl ether. An oil layer is formed and the diethyl ether layer is decanted and the oil is dissolved in 5 ml of 0.1N methanolic hydrogen chloride. The resulting solution is added to 50 ml of diethyl ether, yielding 0.050 g of solid.

MS(FAB): m/z 584(M+H)

Claims

1. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal a pharmacologically effective amount of a compound of the formula: wherein: and when R1=methyl or ethyl, and when R1=n-propyl, and when R1=1-methylethyl, and when R1=n-butyl, and when R1=1-methylpropyl, and when R=R4(CH2)n CO— and n−0 n=0,

X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR1R2 and R1=hydrogen,
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=2-methylpropyl;
R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and n=0-4;
R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4triazolyl) 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo (C1-C3)-alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl (C1-C3)alkylamino (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9) aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C1-C4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy (C2-C4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C7-C9)aralklamino; (C1-C4)alkoxycarbonylamino substituted (C1-C4) alkyl group; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto (C1-C3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalcylcarbonyl cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or napthoyl; halo substituted (C6-C10)aroyl; (C1-C4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or a substituted vinyl group with substitution selected from (C1-C3) alkyl, halogen, (C6-C10)aryl selected from phenyl, α-napthyl, β-naphthyl, halo(C1-C3)alkyl, or a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C3)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C1-C4)alkoxy group; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1methylethyl 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2 W(CH2)2— —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; and when R=R4 (CH2)nCO— and n−1−4 n=1-4,
R4 is selected from hydrogen; amino; straight or branched (C1-C4) alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted(C6-C10)-aryl group with substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C10)aralkyl; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6) cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3) alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3) alkylamino or carboxy; (C7-C8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C1-C6)-alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methyethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C2-C5)azacycloalkyl group; a carboxy(C2-C4)alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methyethyl or α-hydroxypropyl; halo(C1-C3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonylamino, group (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRb-amino(C1-C4)alkoxy group wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, methylpropyl, or 2-methylpropyl or RaRb is (CH)m (CH2)m, m=2-6 or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB, and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl, and when R=R4′ (CH2)nSO2— and n=0
R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6) cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3) acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)-alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9)aralkyl; halo(C1-C3)alkyl group; a heterocycle as defined hereinabove;
RaRb amino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)-alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3) alkyl; and when R=R4′ (CH2)nSO2— and n=1-4,
R4′ is selected from hydrogen; straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1methylpropyl 1-methylpropyl, 2-methyl-propyl or 1,1-dimethylethyl; (C1-C4) carboxyalkyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6) cycloalkyl group with substitution selected from (C1-C3) alkyl, cyano, amino or (C1-C3)-acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, tri-halo(C1-C3) alkyl, nitro, amino, cyano, (C1-C4) alkoxy-carbonyl, (C1-C3) alkylamino or carboxy; (C7-C9)aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3) alkylamino; (C7-C10)aralkyloxy; RaRb amino (C1-C4) alkoxy wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, or NOB —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; (C1-C3) alkylthio selected from methylthio, ethylthio or n-propylthio; C6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C8) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di- straight or branched (C1-C6)alkyl- amino group with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C1-C3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10) aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl, (C1-C4) alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl;
R5 is selected from hydrogen; straight or branched (C1-C3) alkyl selected from methyl, ethyl n-propyl ethyl, n-propyl or 1-methylethyl; (C6-C10) aryl selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9) aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected form from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)-aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
or R5 and R6 taken together are —(CH2)2 W(CH2)2— wherein W is selected from (CH2)q and q=0-1, —NH, —N(C1-C3)—alkyl —N(C1-C3)alkyl, —N(C1-C4) alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

2. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount of a compound of the formula: wherein: and when R1=methyl or ethyl, and when R1=n-propyl, and when R1=1-methylethyl, and when R1=n-butyl, and when R1=1-methylpropyl, and when R=R4(CH2)n CO— and n−0 n=0, and when R=R4 (CH2)nCO— and n−1−4 n=1-4,

X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; is R1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R2 is selected from methyl, ethyl n-propyl ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR1R2 and R1=hydrogen,
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=2-methylpropyl;
R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and n=0-4;
R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)—alkyl trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl (C1-C3)alkylamino (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9) aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C1-C4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy (C2-C4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C7-C9)aralkylamino; (C1-C4)alkoxycarbonylamino substituted (C1-C4) alkyl group; α-hydroxy(C1-C3)alkyl selected from hydromethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto (C1-C3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalcylcarbonyl (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or a substituted vinyl group with substitution selected from (C1-C3) alkyl, halogen, (C6-C10)aryl selected from phenyl, α-naphthyl, β-naphthyl, halo(C1-C3)alkyl, or a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C1-C4)alkoxy group; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1methylethyl 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2 W(CH2)2— —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O,S, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl;
R4 is selected from hydrogen; amino; straight or branched (C1-C4) alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl,, 1-methylpropyl, 2-methylpropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphyhyl β-naphthyl; a substituted(C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C10)aralkyl; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6) cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzyl or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; C6-arylsulfinyl C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3) alkylamino or carboxy; (C7-C8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C1-C6)-alkylamino (C1-C6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C2-C5)azacycloalkyl group; a carboxy(C2-C4)alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonylamino, (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRb-amino(C1-C4)alkoxy group wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH)mm=2-6 (CH2)m, m=2-6 or —(CH2)2W(CH2)2-wherein —(CH2)2W(CH2)2—wherein W is selected from —N(C1-C3)-alkyl, O, S, —NH, —NOB, and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl, O,S, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl, and when R=R4′ (CH2)nSO2— and n=0
R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3) acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl β-naphthyl or B-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9)aralkyl; halo(C1-C3)alkyl group; a heterocycle as defined hereinabove; RaRb amino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)-alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3) alkyl; and when R=R4′ (CH2)nSO2— and n=1-4,
R4′ is selected from hydrogen; straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methyl-propyl or 1,1-dimethylethyl; (C1-C4) carboxyalkyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6) cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)-acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, tri-halo(C1-C3) alkyl, nitro, amino, cyano, (C1-C4)alkoxy-carbonyl, (C1-C3) alkylamino or carboxy; (C7-C9)aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3) alkylamino; (C7-C10)aralkyloxy; RaRb amino (C1-C4) alkoxy, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, or NOB —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; (C1-C3) alkylthio selected from methylthio, ethylthio or n-propylthio; C6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C8) aralkythio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched (C1-C6)alkyl- amino group with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C1-C3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10) aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl ethyl, n-propyl or 1-methylethyl; (C6-C10) aryl selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9) aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected form from methyl, ethyl, n-propyl, or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)-aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)q and q=0-1, —NH, —N(C1-C3)-alkyl, —N(C1-C4) alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

3. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal a pharmacologically effective amount of a compound of the formula: wherein: and when R1=methyl or ethyl, and when R1=n-propyl, and when R1=1-methylethyl, and when R1=n-butyl; and when R1=1-methylpropyl, and when R=R4(CH2)n CO— and n=0, and when R=R4 (CH2)nCO— and n=1-4,

X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR1R2 and R1=hydrogen,
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-methylpropyl or 2-methylpropyl;
R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=2-methylpropyl;
R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and n=0-4;
R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morphonlinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4) alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9) aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C1-C4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy (C2-C4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C7-C9)aralkylamino; (C1-C4)alkoxycarbonylamino substituted (C1-C4) alkyl group; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto (C1-C3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or a substituted vinyl group with substitution selected from (C1-C3) alkyl, halogen, (C6-C10)aryl selected from phenyl, α-naphthyl, β-naphthyl, halo(C1-C3)alkyl, or a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C1-C4)alkoxy group; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl;
R4 is selected from hydrogen; amino; straight or branched (C1-C4) alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted(C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C10)aralkyl; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6) cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzyl or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3) alkylamino or carboxy; (C7-C8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C1-C6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C2-C5)azacycloalkyl group; a carboxy(C2-C4)alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRb-amino(C1-C4)alkoxy group wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6 or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl, O, S, —NH, —NOB, and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl, and when R=R4′ (CH2)nSO2— and n=0
R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6) cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3) acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9)aralkyl; halo(C1-C3)alkyl group; a heterocycle as defined hereinabove; RaRb amino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)-alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3) alkyl; and when R=R4′ (CH2)nSO2— and n=1-4,
R4′ is selected from hydrogen; straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methyl-propyl or 1,1-dimethylethyl; (C1-C4) carboxyalkyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6) cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)-acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, tri-halo(C1-C3) alkyl, nitro, amino, cyano, (C1-C4)alkoxy-carbonyl, (C1-C3) alkylamino or carboxy; (C7-C9)aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3) alkylamino; (C7-C10)aralkyloxy; RaRb amino (C1-C4) alkoxy, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, or —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; (C1-C3) alkylthio selected from methylthio, ethylthio or n-propylthio; C6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C8) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched (C1-C6)alkyl- amino group with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C1-C3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10) aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9) aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)-aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)q and q=0-1, —NH, —N(C1-C3)-alkyl, —N(C1-C4) alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D) rolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

4. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal having a bacterial infection a pharmacologically effective amount of a compound of formula I: wherein X is selected from amino, NR1R2, or halogen, the halogen is selected from bromine, chlorine, fluorine or iodine, and when X is NR1R2, R1 is methyl or ethyl and R2 is methyl or ethyl; R is R4(CH2)nCO—; n is 1-4; and R4 is monosubstituted or disubstitued amino selected from straight or branched (C1-C6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.

5. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal having a bacterial infection a pharmacologically effective amount of a compound of formula I: wherein X is N(CH3)2 and R is R4(CH2)nCO— where n=1-4 and R4 is monosubstituted or disubstituted amino selected from straight or branched (C1-C6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.

6. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal having a bacterial infection a pharmacologically effective amount of a compound of formula I: wherein X is N(CH3)2 and R is R4(CH2)nCO— where n is 1 and R4 is monosubstituted or disubstituted amino selected from straight or branched (C1-C6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.

7. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal having a bacterial infection a pharmacologically effective amount of a compound of formula I: wherein R4 is a monosubstituted straight or branched C4-alkylamino, and pharmacologically acceptable organic and inorganic salts or metal complexes.

8. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount of a compound of the formula: wherein: and when R1=methyl or ethyl, and when R1=n-propyl, and when R1=1-methylethyl, and when R1=n-butyl, and when R1=1-methylpropyl, and when R=R4(CH2)n CO— and n=0, and when R=R4 (CH2)nCO— and n=1-4,

X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR1R2 and R1=hydrogen,
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
R2=2-methylpropyl;
R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and n=0-4;
R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4) alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9) aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C1-C4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy (C2-C4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C7-C9)aralkylamino; (C1-C4)alkoxycarbonylamino substituted (C1-C4) alkyl group; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto (C1-C3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or a substituted vinyl group with substitution selected from (C1-C3) alkyl, halogen, (C6-C10)aryl selected from phenyl, α-naphthyl, β-naphthyl, halo(C1-C3)alkyl, or a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C1-C4)alkoxy group; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl;
R4 is selected from hydrogen; amino; straight or branched (C1-C4) alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted(C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C10)aralkyl; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6) cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzyl or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3) alkylamino or carboxy; (C7-C8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C1-C6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C2-C5)azacycloalkyl group; a carboxy(C2-C4)alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRb-amino(C1-C4)alkoxy group wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6 or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl, O, S, —NH, —NOB, and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl, and when R=R4′ (CH2)nSO2— and n=0
R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6) cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3) acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9)aralkyl; halo(C1-C3)alkyl group; a heterocycle as defined hereinabove; RaRb amino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)-alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3) alkyl; and when R=R4′ (CH2)nSO2— and n=1-4,
R4′ is selected from hydrogen; straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methyl-propyl or 1,1-dimethylethyl; (C1-C4) carboxyalkyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6) cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)-acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, tri-halo(C1-C3) alkyl, nitro, amino, cyano, (C1-C4)alkoxy-carbonyl, (C1-C3) alkylamino or carboxy; (C7-C9)aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3) alkylamino; (C7-C10)aralkyloxy; RaRb amino (C1-C4) alkoxy, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, or —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; (C1-C3) alkylthio selected from methylthio, ethylthio or n-propylthio; C6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C8) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched (C1-C6)alkyl- amino group with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C1-C3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10) aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9) aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)-aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)q and q=0-1, —NH, —N(C1-C3)-alkyl, —N(C1-C4) alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.

9. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount as of compound of formula I: wherein X is selected from amino, NR1R2, or halogen, the halogen is selected from bromine, chlorine, fluorine or iodine, and when X is NR1R2, R1 is methyl or ethyl and R2 is methyl or ethyl; R is R4(CH2)nCO—; n is 1-4; and R4 is monosubstituted or disubstituted amino selected from straight or branched chain (C1-C6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.

10. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount as of compound of formula I: wherein X is N(CH3)2 and R is R4(CH2)nCO— where n=1-4 and R4 is monosubstituted or disubstituted amino selected from straight or branched (C1-C6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.

11. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount as of compound of formula I: wherein X is N(CH3)2and R is R4(CH2)nCO— where n is 1 and R4 is monosubstituted or disubstituted amino selected from straight or branched (C1-C6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.

12. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount as of compound of formula I: wherein R4 is a monosubstituted straight or branched C4-alkylamino, and pharmacologically acceptable organic and inorganic salts or metals complexes.

Referenced Cited
U.S. Patent Documents
2482055 September 1949 Duggar
2619420 November 1952 Jukes
2731497 January 1956 Erickson
2734018 February 1956 Minieri et al.
2878289 March 1959 McCormick et al.
2911339 November 1959 Goodman
2997471 August 1961 Cheney et al.
3007965 November 1961 Growich et al.
3023239 February 1962 Origoni et al.
3026248 March 1962 Noseworthy et al.
3043875 July 1962 Beereboom et al.
3050558 August 1962 Smith et al.
3092556 June 1963 Growich, Jr. et al.
3128227 April 1964 Kanegis et al.
3145228 August 1964 Schach von Wittenau et al.
3148212 September 1964 Boothe et al.
3200149 August 1965 Blackwood et al.
3219529 November 1965 Nash et al.
3226436 December 1965 Petisi et al.
3239499 March 1966 Rennhard et al.
3250809 May 1966 Blackwood et al.
3250810 May 1966 Blackwood et al.
RE26253 August 1967 Petisi et al.
3338963 August 1967 Petisi et al.
RE26271 September 1967 Boothe et al.
3341585 September 1967 Bitha et al.
3345410 October 1967 Winterbottom et al.
3360557 December 1967 Shu
3360561 December 1967 Zambrano
3373196 March 1968 Bitha et al.
3373197 March 1968 Martell et al.
3373198 March 1968 Martell et al.
3397230 August 1968 Winterbottom et al.
3403179 September 1968 Zambrano
3433834 March 1969 Winterbottom et al.
3483251 December 1969 Lawrence et al.
3502696 March 1970 Conover
3509184 April 1970 Conover et al.
3515731 June 1970 Conover
3518306 June 1970 Martell et al.
3526629 September 1970 Martell, Jr. et al.
3579579 May 1971 Hlavka et al.
3586483 June 1971 Haklar et al.
3697552 October 1972 Conover et al.
3772363 November 1973 Conover et al.
3809751 May 1974 Abbey
3812188 May 1974 Ziegler
3829453 August 1974 Conover et al.
3849493 November 1974 Conover et al.
3862225 January 1975 Conover et al.
3901942 August 1975 Bernardi et al.
3978000 August 31, 1976 Schmitt, Jr. et al.
4029600 June 14, 1977 Schmitt, Jr. et al.
4031137 June 21, 1977 Schmitt, Jr. et al.
4038315 July 26, 1977 Tobkes
4081370 March 28, 1978 Schmitt, Jr. et al.
4666897 May 19, 1987 Golub et al.
4837030 June 6, 1989 Valorose, Jr. et al.
4911924 March 27, 1990 Griffith et al.
4918208 April 17, 1990 Hasegawa et al.
4925833 May 15, 1990 McNamara et al.
4975271 December 4, 1990 Dunn et al.
5021407 June 4, 1991 Levy
5045538 September 3, 1991 Schneider et al.
5122519 June 16, 1992 Ritter
5143661 September 1, 1992 Lawter et al.
5240272 August 31, 1993 Halabiya
5248797 September 28, 1993 Sum
5280888 January 25, 1994 Brandener
5281628 January 25, 1994 Hlavka et al.
5284963 February 8, 1994 Sum et al.
5326759 July 5, 1994 Hlavka et al.
5328902 July 12, 1994 Sum et al.
5380888 January 10, 1995 Sum et al.
5384259 January 24, 1995 Rothstein et al.
5386041 January 31, 1995 Sum et al.
5401729 March 28, 1995 Sum et al.
5401863 March 28, 1995 Hlavka et al.
5420272 May 30, 1995 Sum et al.
5430162 July 4, 1995 Sum et al.
5442059 August 15, 1995 Sum et al.
5457096 October 10, 1995 Sum et al.
5466684 November 14, 1995 Sum et al.
5495018 February 27, 1996 Sum et al.
5495030 February 27, 1996 Sum et al.
5495031 February 27, 1996 Sum et al.
5495032 February 27, 1996 Sum et al.
5512553 April 30, 1996 Sum et al.
5567692 October 22, 1996 Sum et al.
5675030 October 7, 1997 Krishnan et al.
5789188 August 4, 1998 Rothstein et al.
5886175 March 23, 1999 Sum et al.
Foreign Patent Documents
109 850 May 1984 EP
901107 July 1962 GB
WO 84/01895 May 1984 WO
WO 89/02270 March 1989 WO
Other references
  • Chopra, Handbook of Experimental Pharmacology, vol. 78, pp. 317-392, Springer-Verlay (1985).
  • Levy, Antimicrobial Agents & Chemotherapy, vol. 33(8), pp. 1373-1374, (Aug. 1989).
  • Salyers, Molecular Microbiology, vol. 4(1), pp. 151-156 (1990).
  • Adamson et al., “Aplastic Anemia,” Hematology 4th ed., Williams WJ et al, eds.; McGraw Hill, New York (1990) pp. 158-174.
  • Allen, “Minocycline,” Ann. Intern. Med. 85:482-487 (1976).
  • Altemeier et al., “Intra-abdominal Abscesses,” American Journal of Surgery 125:70-79 (1973).
  • Bell, “Oral Penicillins in the Treatment of Chronic Staphylococcal Osteomyelitis,” Lancet 10:295-297 (1968).
  • Benitz et al., “Morphologic Effects of Minocycline in Laboratory Animals,” Toxicol. Appl. Pharmacol. 11:150-170 (1967).
  • Bennion et al., “Gangrenous and Perforated Appendicitis with Peritonitis: Treatment and Bacteriology,” Clinical Therapeutics 12(Suppl C):31-44 (1990).
  • Bocker et al., “Identification and Determination of the Principal Metabolites of Minocycline in Humans,” J. Chromatogr. 568:363-374 (1991).
  • Bohnen et al., “Prognosis in Generalized Peritonitis. Relation to Cause and Risk Factors,” Archives of Surgery 118:285-290 (1983).
  • Boothe et al., “6-Deoxytetracyclines, I. Chemical Modification by Electrophilic Substitution” J. Am. Chem. Soc., 82:1253-1254 (1960).
  • Bryant et al., “Increased Frequency of Doxycycline Side Effects,” Pharmacotherapy 7:125-129 (1987).
  • Buyske et al., “Concentration and Persistence of Tetracycline and Chlortetracycline in Bone,” J. Pharmacol. Exper. Ther. 130:150-156 (1960).
  • Ciancio et al., “An Evaluation of Minocycline in patients with Periodontal Disease”, Journal of Periodontology 51:530-534 (1980).
  • Collins, “Cell-Free Synthesis of Proteins Coding for Mobilisation function of colE1 and Transportation” Gene 6:28-42 (1979).
  • Conte et al., “Steady-State Serum and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Tigecycline,” Int. J. Antimicrob. Agents 25(6):523-529 (2005).
  • Degenkolb et al., “Structural Requirements of Tetracycline-tet Repressor Interaction: Dermination of Equilibrium Binding Constants for Tetracycline Analogs with the Tet Repressor”, Antimicrob. Agents Chemother. 35:1591-1595 (1991).
  • DeJonge et al., “Inhibition of Mitochondrial-Protein Synthesis in Rat Small-Intestinal Epithelium,” Eur. J. Biochem. 32:356-364 (1973).
  • Dietz et al., “Comparative Toxicity and Carcinogenicity Studies of Tetracycline and Oxytetracycline in Rats and Mice,” Fund. Appl. Toxicol. 17:335-346 (1991).
  • Entwistle et al. “,Reduction of Nitro-compounds”, J. Chem. Soc. 1:443 (1977).
  • Fanning et al., “Distressing Side-effects of Minocycline Hydrochloride,” Arch Intern Med. 136:761-762 (1976).
  • Feigin, “Clindamycin Treatment of Osteomyelitis and Septic Arthritis in Children,” Pediatr. 55:213-223 (1975).
  • Fry et al., “Determinants of Death in Patients with Intraabdominal Abscess,” Surgery 88:517-523 (1980).
  • Garrison, “Histamine, Bradykinin, 5-Hydroxytryptamine, and Their Antagonists,” In: Gilman AG, Rall TW et al., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics 8th ed. Elmsford, NY: Pergamon Press pp. 575-582 (1990).
  • Gibaldi et al., Pharmacokinetics, 2nd ed., “One-Compartment”, Marcel Dekker, Inc., NY, 1982, pp. 1-43.
  • Gorbach, “Antimicrobial Prophylaxis for Appendectomy and Colorectal Surgery,” Reviews of Infectious Diseases 13(Suppl 10):S815-S820 (1991).
  • Gugler et al., “Effects of Antacids on the Clinical Pharmacokinetics of Drugs. An Update,” Clin. Pharmacokinet. 18:210-219 (1990).
  • Gump et al., “Side Effects of Minocycline: Different Dosage Regimen,” Antimicrob Agents Chemother. 12:642-646 (1977).
  • Hlavka et al., “The 6-Deoxytetracyclines. III Electrophilipic and Nucleophilic Substitution”, J. Am. Chem. Soc., 84:1426-1430 (1962).
  • Jonas et al., “Minocycline,” Ther. Drug Monit. 4:137-145 (1982).
  • Kantrowitz et al., “Histamine-Mediated Myocardial Damage in Rabbits,” J. Mol. Cell. Cardiol. 14:551-555 (1982).
  • King, “Animal Models in the Study of Vomiting,” Can. J. Physiol. Pharmacol. 68:260-268 (1990).
  • Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, (1989).
  • Loeliger et al., “Reliability and Clinical Impact of the Normalization of the Prothrombin Times in Oral Anticoagulant Control”, Thrombosis & Haemostasis 53:148-154 (1985).
  • MacDonald et al., “Pharmacokinetic Studies on Minocycline in Man,” Clinical Pharmacology and Therapeutics 14:852-861 (1973).
  • Misgen, “Compatibilities and Incompatibilities of Some Intravenous Solution Admixtures”, Am. J. Hosp. Pharm. 22:92-94 (1965).
  • Mitscher, “The Chemistry of the Tetracycline Antiobiotic”, Marcel Dekker, Inc. Chapter 6.3, p. 172-173 and Chapter 2, p. 53-54, (1978).
  • Monnier et al., “Visual Compatibility of Heparin with Selected Intravenous Admixtures”, ASHP Midyear Clinical Meeting, vol. 25, p. P-186E (Dec. 1990).
  • Mosdell et al., “Antibiotic Treatment for Surgical Peritonitis,” Annals of Surgery 214:543-549 (1991).
  • Morrison et al., “Amines I. Preparation and Physical Properties”, Organic Chemistry, 4th ed., pp. 894, 898-900, 902 (1983).
  • Nelis et al., “Metabolism of Minocyclinein Humans,” Drug Metab Dispos. 10:142-146 (1982).
  • Noble et al., “Short-term Toxicity and Observations on Certain Aspects of the Pharmacology of a Unique Tetracycline-Minocycline,” Toxicol. Appl. Pharmacol. 11:128-149 (1967).
  • Norden, “Lessons Learned from Animal Models of Osteomyelitis,” Rev. Infect. Dis. 10:103-110 (1988).
  • Norden, “Experimental Chronic Staphylococcal Osteomyelitis in Rabbits: Treatment with Rifampin Alone and in Combination with Other Antimicrobial Agents,” Rev. Infect. Dis. 5(Suppl 3):S491-494 (1983).
  • Norden et al., “Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus with Vancomycin and Rifampin,” J. Infect. Dis. 147:352-357 (1983).
  • Norden et al., “Clindamycin Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus,” J. Infect. Dis. 153:956-959 (1986).
  • Norden et al., “Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus with Ampicillin/Sulbactam,” J. Infect. Dis. 161:52-53 (1990).
  • Pawelczyk et al., “Kinetics of Drug Decomposition Part 74.Kinetics of Degradation of Minocycline in Aqueous Solution”, Pharmacol. Pharm. 34:409-421 (1982).
  • Pratt, Coupled TranScription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B.D. Hames and S.J. Higgins, eds.) p. 179-209, IRL Press, Oxford-Washington, (1984).
  • Raasch,“Interaction of Oral Antibiotics and Common Chronic Medications” Geriatrics 42:69-74 (1987).
  • Remmers et al., “Some Observations on the Kinetics of the C.4 Epimerization of Tetracycline,” J. Pharm. Sci. 52:752-756 (1963).
  • Robertson, “p-Aminophenyllacetic Acid”, Org. Syn. Coll. 1:52 (1941).
  • Rissing, “Animal Models of Osteomyelitis: Knowledge, Hypothesis and Speculation,” Infect. Dis. Clin. North Am. 4:377-390 (1990).
  • Skillman et al., “Respiratory Failure, Hypotension, Sepsis, and Jaundice. A Clinical Syndrome Associated with Lethal Hemorrhage from Acute Stress Ulceration of the Stomach,” American Journal of Surgery 117:523-530 (1969).
  • Slama et al., “Oral Ciprofloxacin Therapy for Osteomyelitis Caused by Aerobic Gram Negative Bacilli,” Am. J. Med. 82(Suppl 4A):259-261 (1987).
  • Solomkin et al., “Results of a Multicenter Trial Comparing Imipenem/Cilastatin to Tobramycin/Clindamycin for Intra-abdominal Infections,” Annals of Surgery 212:581-591 (1990).
  • Spencer et al., “6-Deocytetracyclines,. V. 7,9-Disubstituted Products”, J. Med. Chem. 6:405-407 (1963).
  • Sum et al., “Synthesis of Novel Tetracycline Derivatives with Substitution at the C-8 Position,” Tetrahedron Letters vol. 35, No. 12, pp. 1835-1836 (1994).
  • Swenson et al. “The Bacteriology of Intra-abdominal Infections,” Archives of Surgery 109:398-399 (1974).
  • Tapp et al., “Tetracycline Toxicity,” Experientia 22:530-531 (1966).
  • Tice, “Outpatient Parenteral Antimicrobial Therapy for Osteomyelitis,” Infect. Dis. Clin. North Am. 12:903-919 (1998).
  • Van Den Bogert et al., “Tissue distribution and Effects on Mitochondrial Protein Synthesis of Tetracyclines After Prolonged Continuous Intravenous Administration to Rats,” Biochem. Pharmacol. 30:1706-1709 (1981).
  • Waldvogel, “Osteomyelitis,” In Gorbach SL et al., eds. Infectious Diseases, Saunders, Philadelphia 1339-1344 (1988).
  • Westfall et al., “Formulation of a Stable Trace Element Solution for TPN” Am. J. Hosp. Pharm. 37:1620 (1980).
  • Watson, “Chloramphenicol Toxicity in Dogs,” Research in Veterinary Science 23:66-69 (1977).
  • Williams et al., “Minocycline: Possible Vestibular Side-Effects,” Lancet. 2:744-746 (1974).
  • Woodward, “m-Hydroxybenzaldehyde”, Org. Syn. Coll. 3:453 (1955.
  • Yuen, et al., “Kinetics of Concomitatnt Degradation of Tetracycline to Epitetracycline to Epitetracycline, Anhydrotetracycline, and Epianhydrotetracycline in Acid Phosphate Solution”, J. Pharm. Sci. 66:1648-1650 (1977).
  • Zubay, “In-vitro Synthesis of Protein in Microbial Systems”, Ann. Rev. Genet. 7:267-287 (1973).
  • The Merck Index, Entries #2111 and 5936 10th Ed. (1983) pp. 300,301, & 869.
  • World Health Organization Technical Report Series 687:1-184 (1983).
Patent History
Patent number: RE40086
Type: Grant
Filed: Dec 23, 2005
Date of Patent: Feb 19, 2008
Assignee: Wyeth Holdings Corporation (Madison, NJ)
Inventors: Joseph J. Hlavka (Tuxedo Park, NY), Phaik-Eng Sum (Pomona, NY), Yakov Gluzman (Upper Saddle River, NJ), Ving J. Lee (Los Altos, CA), Adma A. Ross (Airmont, NY)
Primary Examiner: Barbara P. Badio
Application Number: 11/318,390
Classifications
Current U.S. Class: 3,10-dihydroxy-2-naphthacene Carboxamide Or Derivative (e.g., Tetracycline, Etc.) Doai (514/152)
International Classification: A61K 31/65 (20060101);